| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sinovac Biotech, Ltd$6.47
-0.02 (-0.31%)
C 54Pipeline Score Fair Value Pharma · Clinical
Market Cap
464.94 M
EPS
-
P/E Ratio
-
Value Trade
53.43 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
8.23 K
52 Week Range
-
% held by Insiders
-
% held by Institutions
-
Enterprise Value
-
Total Shares
71.80 M
Short %
0.45 %
Float Shares
18.45 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sinovac Biotech, Ltd
764Total events
1Upcoming
191Tier-1 (high impact)
2004 – 2026Coverage
Upcoming catalysts 1
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
◆FDA Filing AcceptedRegulatory Filing
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C54
Pipeline Score $1.0B
Pipeline ValueFair Value
Valuation Signal30
Drugs Scored2.2x
rNPV / MCap Top 83%
Micro Cap (rank 156 of 913)
Percentile RankSinovac Biotech, Ltd carries a moderate pipeline score (54/100), with $3.4B risk-adjusted pipeline value, led by Sinovac PCV13 in Pneumococcal Infectious Diseases (Phase 3), across $106B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinovac PCV13 Monoclonal antibody | Pneumococcal Infectious Disease | Phase 3 | NCT06183216 | 65% | $1.3B | COMPLETED | 3,820 | - | - | Mar 26, 2025 | - | Jan 28, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
sIPV | Polio | Phase 3 | 2019-04-16 | seroconversion rate type 1: 98.0%; seroconversion rate type 2: 94.8%; seroconversion rate type 3: 98.9%; ipv seroconversion rate type 1: 94.1%; ipv seroconversion rate type 2: 84.0%; ipv seroconversion rate type 3: 97.7% Read More | Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease The Sinovac-developed sIPV demonstrates both long-term affor Read More | |
sIPV | Polio | Phase 3 | 2019-04-16 | seroconversion rate type 1: 98.0%; seroconversion rate type 2: 94.8%; seroconversion rate type 3: 98.9%; ipv seroconversion rate type 1: 94.1%; ipv seroconversion rate type 2: 84.0%; ipv seroconversion rate type 3: 97.7% Read More | Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease The Sinovac-developed sIPV demonstrates both long-term affor Read More | |
sIPV | Polio | Phase 3 | 2019-04-16 | seroconversion rate type 1: 98.0%; seroconversion rate type 2: 94.8%; seroconversion rate type 3: 98.9%; ipv seroconversion rate type 1: 94.1%; ipv seroconversion rate type 2: 84.0%; ipv seroconversion rate type 3: 97.7% Read More | Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease The Sinovac-developed sIPV demonstrates both long-term affor Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SVA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SVA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-SVA
Jun 15, 2026SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements
SINOVAC has regained compliance with the Nasdaq Global Market's listing requirements, indicating a positive step for the company. This compliance suggests that SINOVAC has met the necessary financial and operational standards set by Nasdaq. The news may impact investor confidence and market perception positively.
Read more →-SVA
Jun 5, 2026SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
SINOVAC has reported its unaudited and unreviewed financial results for the second half of 2025. The company has also filed its 2025 Annual Report on Form 20-F. However, the unaudited nature of the results may raise concerns among investors regarding the reliability of the financial data.
Read more →-SVA
May 29, 2026SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
SINOVAC has been notified by Nasdaq about the late filing of its 2025 Annual Report. This notification indicates potential compliance issues that may affect the company's standing on the exchange. Investors may view this delay as a negative signal regarding the company's financial reporting practices.
Read more →-SVA
May 21, 2026SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
SINOVAC has announced an extension of the deadline for shareholders to submit payment instructions for its previously declared special cash dividend. This decision aims to ensure that all eligible shareholders have adequate time to participate in the dividend distribution. The announcement reflects the company's commitment to shareholder engagement and transparency.
Read more →-SVA
May 8, 2026SINOVAC Reports Unaudited First Half of 2025 Financial Results
SINOVAC has reported its unaudited financial results for the first half of 2025. The report lacks detailed insights, leading to concerns about the company's financial health. Investors may find the absence of comprehensive data troubling as it could impact future business decisions.
Read more →-SVA
Apr 30, 2026SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
Sinovac Biotech Ltd. has filed its annual report on Form 20-F for the fiscal year 2024 with the SEC. The report highlights the company's extensive portfolio of vaccines and its commitment to combating infectious diseases. Sinovac continues to innovate and expand its global presence, aiming to enhance vaccine development and accessibility.
Read more →-SVA
Jan 22, 2026SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
Sinovac Biotech Ltd. has received approval from the Nasdaq Hearings Panel to continue its listing, contingent upon meeting specific financial filing requirements by May 11, 2026. The company is collaborating with Zhonghua Certified Public Accountants LLP to ensure compliance with Nasdaq rules and complete necessary audits. Sinovac remains focused on maintaining its commitment to regulatory obligations.
Read more →-SVA
Jan 5, 2026Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
Sinovac Biotech Ltd. has received a notification from Nasdaq regarding its late filing of the 2025 half-year report. The company is scheduled to present its case to the Nasdaq Hearings Panel on January 8, 2026, in an effort to maintain its listing. This follows a previous delisting determination received in November 2025.
Read more →-SVA
Jan 2, 2026Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report BEIJING - Sinovac Biotech Ltd. (NASDAQ: SVA) (" SINOVAC " or the " Company "), a leading provider of biopharmaceutical products in China
Sinovac Biotech Ltd. has received a notification from Nasdaq indicating that it failed to comply with its Listing Rule regarding timely filing. This notification follows a previous delisting determination that the company is contesting at a scheduled hearing. Sinovac is preparing to present its views to the Nasdaq Hearings Panel in hopes of maintaining its listing. The company has a history of providing biopharmaceutical products and vaccines in China.
Read more →-SVA
Dec 17, 2025SINOVAC BIOTECH LIMITED PRESS RELEASE Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting BEIJING -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (NAS
Sinovac Biotech Ltd. announced that the Antigua High Court has granted control of the company’s board to its current members until a trial regarding a disputed shareholder meeting takes place in late April or early May 2026. The decision follows a hearing related to the composition of the board during an ongoing dispute. In a recent board meeting, the directors reaffirmed their commitment to enhancing shareholder value and stability while addressing current challenges, including restoring NASDAQ trading for their shares. Sinovac continues to focus on its mission to supply vaccines and improve health outcomes globally.
Read more →-SVA
Nov 18, 2025SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal BEIJING
Sinovac Biotech Ltd. has announced that it received a delisting notice from Nasdaq due to its failure to file the 2024 Annual Report by the deadline. The company intends to appeal this decision, requesting a hearing before the Nasdaq Hearing Panel as it seeks to regain compliance with the listing requirements. The appeal process will temporarily halt the suspension of its securities. Sinovac is currently collaborating with a new accounting firm to expedite the filing of required reports.
Read more →-SVA
Oct 24, 2025SINOVAC Announces Appointment of Independent Auditor BEIJING - The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in
SINOVAC Biotech Ltd. (NASDAQ: SVA) has appointed UHY LLP as its independent auditor, starting from October 24, 2025. The appointment aims to enhance financial oversight and ensure compliance with SEC and NASDAQ requirements. UHY will oversee the audits of SINOVAC's financial statements for several years, including internal controls. The company emphasizes the importance of transparency in conjunction with its ongoing business goals and potential trading resumption on NASDAQ.
Read more →-SVA
Jul 10, 2025SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board Special Meeting was validly adjourned until the appropriate court can make a final decision on the validity
SINOVAC Biotech's Board of Directors has strongly rejected claims made by SAIF and the former board regarding a Special Meeting of Shareholders. The Board asserts that the Special Meeting was validly adjourned pending a court decision on the validity of PIPE shares. They emphasize that the current Board remains the legitimate governing body and is committed to protecting shareholder interests amidst ongoing legal disputes. The company plans to pursue legal remedies against perceived unlawful actions taken by SAIF and the former board.
Read more →-SVA
Jul 10, 2025Newly Elected Directors of Sinovac Hold the First Board Meeting Mr. Andrew Y. Yan elected Chairman of the Board New Board Unanimously Resolved to Explore Future Dividend Plans, Conduct Search for New Auditor for Resuming
Sinovac Biotech Ltd. has announced that its newly elected board of directors held their first meeting, electing Andrew Y. Yan as Chairman. The board unanimously resolved to explore future dividend plans and seek a new auditor to facilitate the resumption of NASDAQ trading. They emphasized their commitment to restoring stable operations and resolving ongoing litigations with shareholders. The board also stated their support for the existing management team, highlighting a focus on enhancing transparency and shareholder trust.
Read more →-SVA
Jul 9, 2025SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares On July 7 Antigua Court restricted PIPE shares from
SINOVAC Biotech Ltd. has announced the adjournment of its Special Meeting of Shareholders pending a court decision on the validity of certain PIPE shares, which were restricted from voting by a recent injunction. The situation arose from litigation in Antigua, where the former board's PIPE transaction is being challenged. A temporary stay from the Eastern Caribbean Court of Appeal allows for a limited ability for those shares to vote while legal proceedings continue. Meanwhile, SINOVAC is distributing a special cash dividend to shareholders, emphasizing its commitment to fairness and governance during this process.
Read more →-SVA
Jul 8, 2025Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place ISS states, "[T]he [current] board appears to be working to pay SVA shareholders
Institutional Shareholder Services Inc. (ISS) has aligned with Glass Lewis in advising Sinovac shareholders to retain the current board. This recommendation follows the board's efforts to improve shareholder value by instituting a significant dividend and working towards resuming trading of company shares. The current board has taken swift actions to rectify the governance failures of the previous board, which had a detrimental impact on shareholder value. The upcoming special meeting will allow shareholders to vote against the proposals to remove the current board.
Read more →-SVA
Jul 2, 2025Leading Independent Proxy Advisory Firm Glass Lewis Recommends SINOVAC Shareholders Vote to Keep the Current Board in Place Glass Lewis concludes, "[T]he current board has demonstrated credible progress in restoring gove
Glass Lewis, a leading independent proxy advisory firm, has advised SINOVAC shareholders to vote to keep the current board in place ahead of the special meeting scheduled for July 2025. The advisory firm praised the board for demonstrating credible progress in governance and operational stability. In contrast, Glass Lewis criticized the proposals from the dissident group, citing concerns about their reliability and associations with past governance failures. SINOVAC's board is encouraging shareholders to reject the proposed changes to protect their investments.
Read more →-SVA
Jun 30, 2025SINOVAC Board of Directors Urges Shareholders to Vote the WHITE Proxy Card "AGAINST" the Misguided Proposals to Remove SINOVAC's Current Board Reaffirms Commitment to Declaring Dividends and New Dividend Policy Underscor
SINOVAC's Board of Directors urges shareholders to vote against proposals aimed at removing the current board at the upcoming Special Meeting on July 9, 2025. The board emphasizes its commitment to declare substantial cash dividends and protect shareholder interests amid ongoing legal challenges from a dissenting investor group. They argue that the previous board's actions drained resources and failed to provide dividends while stressing their efforts to restore compliance with NASDAQ and enhance shareholder value. The call to action highlights the importance of shareholder votes in determining the company's future direction and governance.
Read more →-SVA
Jun 24, 2025SINOVAC Board of Directors Files Investor Presentation Outlining Decisive Actions to Protect Shareholder Interests Highlights bold steps to restore fairness to SINOVAC's common shareholders and deliver long-term value cr
SINOVAC Biotech Ltd. has filed an investor presentation with the SEC, detailing measures to protect shareholder interests and promote long-term value creation. The Board of Directors is urging shareholders to vote against proposals that would remove them and to maintain the current governance structure. The presentation addresses past governance failures by the former Board and positions the company for renewed growth. Shareholders are reminded of the importance of voting in the upcoming Special Meeting scheduled for July 9, 2025.
Read more →-SVA
Jun 19, 2025SINOVAC Board of Directors Files Definitive Proxy Materials Files definitive proxy statement and mails letter to shareholders Urges shareholders to VOTE the WHITE proxy card and vote "AGAINST" the misguided proposals to
SINOVAC Biotech Ltd. has filed definitive proxy materials for its Special Meeting of Shareholders, urging shareholders to vote against proposals aimed at removing its current Board of Directors. The board describes the dissenting investor group’s claims as misguided and emphasizes its commitment to delivering shareholder value and stability. The meeting is scheduled for July 9, 2025, and the board highlights the importance of shareholder votes in shaping the company's future. Investors are encouraged to discard any conflicting proxy materials from the dissenting group.
Read more →-SVA
Jun 18, 2025Chairman's Message Dear Shareholders, I would like to inform you that a 2025 Special Meeting (the "Special Meeting") of Shareholders of Sinovac Biotech Ltd. will be held on Tuesday, 8 July 2025 at 8:00 p.m. Atlantic Stan
Sinovac Biotech Ltd. will hold a Special Meeting of Shareholders on July 8, 2025, to discuss the removal of the current Board and potential election of new directors. The current Board advocates against these proposals, emphasizing their commitment to maximizing shareholder value through dividend payments. Recent challenges, including a trading halt and ongoing lawsuits, stem from actions taken by the previous management. The current Board has made strides in improving compliance and exploring future listing opportunities.
Read more →-SVA
Jun 17, 2025SINOVAC Board of Directors Provides Update on Special Dividend Payment and Commitment to Delivering Value to All Shareholders Accelerates payment of previously announced special cash dividend of US$55.00 per common share
SINOVAC Biotech Ltd. announced a series of updates regarding dividends and shareholder governance. The board has accelerated the payment of a special cash dividend of US$55.00 and plans to introduce additional special dividends ranging from US$19.00 to US$50.00. A commitment to regularly return cash to shareholders has been established, alongside an emphasis on improving corporate governance through forthcoming shareholder meetings. However, the board faces challenges from a dissenting investor group pursuing legal action against it.
Read more →-SVA
May 20, 2025SINOVAC BIOTECH LTD. NOTICE OF SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that a Special Meeting of Shareholders of Sinovac Biotech Ltd. (the " Company ") will be held on Tuesday, 8 July 2025 at 8:00 p.m. Atl
Sinovac Biotech Ltd. has announced a Special Meeting of Shareholders on July 8, 2025, which will address significant changes within its Board of Directors. The meeting is called at the request of Cede & Co. and SAIF Partners IV L.P. to consider the removal of certain directors and the election of new ones. Shareholders must be registered by May 19, 2025, to participate, and details regarding proxy voting and meeting materials will be provided in advance. The context includes historical governance disputes regarding shares issued by the previous board.
Read more →-SVA
May 16, 2025SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report BEIJING - Sinovac Biotech Ltd. (NASDAQ: SVA) (" SINOVAC " or the " Company "), a leading provider of biopharmaceutical products in China, t
Sinovac Biotech Ltd. received a notification from Nasdaq regarding its non-compliance with listing rules due to a late filing of its 2024 Annual Report. The company has until July 15, 2025, to submit a Compliance Plan to address the issue. The resignation of the independent accounting firm adds additional challenges to timely filing. If the Compliance Plan is rejected, Sinovac has the option to appeal the decision.
Read more →-SVA
Apr 30, 2025SINOVAC Announces Record and Distribution Dates for Special Cash Dividend BEIJING - Sinovac Biotech Ltd. (NASDAQ: SVA) (" SINOVAC " or the " Company "), a leading provider of biopharmaceutical products in China, today an
Sinovac Biotech Ltd. has declared a special cash dividend of US$55.00 per common share, payable to shareholders as of May 23, 2025. The payment is expected to be made around July 9, 2025. Known for its biopharmaceutical advancements, Sinovac's product offerings include vaccines against several infectious diseases such as COVID-19 and hepatitis A.
Read more →-SVA
Apr 1, 2025SINOVAC Announces Decision to Declare Cash Dividend BEIJING - Sinovac Biotech Ltd. (NASDAQ: SVA) (" SINOVAC " or the " Company "), a leading provider of biopharmaceutical products in China, today announced that the Compa
Sinovac Biotech Ltd. has announced a special cash dividend of $55.00 per common share aimed at rewarding shareholders based on prior distributions from its subsidiaries. The board anticipates that this dividend will be funded from the company's available cash resources. Additionally, the board is evaluating past corporate decisions following a recent ruling that confirmed its legitimacy. This includes scrutiny of certain shares' issuance by the prior board in 2018.
Read more →-SVA
Mar 31, 2025SINOVAC Announces New Board Member and Chairman of the Audit Committee BEIJING - Sinovac Biotech Ltd. (NASDAQ:SVA) ( SINOVAC or the Company ), a leading provider of biopharmaceutical products in China, today announced th
Sinovac Biotech Ltd. has appointed Sven H. Borho as a director and the Chair of the Audit Committee to fill a vacancy on its board. Borho, a qualified financial expert with over 30 years in healthcare investment, brings substantial expertise to the company. The Board now consists of five members, continuing to focus on the development and commercialization of biopharmaceutical products, including vaccines. Sinovac's commitment to innovative vaccine research and development is anticipated to support future market expansion.
Read more →-SVA
Feb 8, 2025SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order BEIJING - Sinovac Biotech Ltd. (NASDAQ:SVA) ( SINOVAC or the Company ), a leading provider of biopharmaceutical products in China, today announced
Sinovac Biotech Ltd. has announced the establishment of a new board following a court ruling that invalidated a previously imposed poison pill agreement. This ruling is expected to facilitate the resumption of trading of the company's shares, which have been halted for six years. The newly appointed board is committed to transparency and prioritizing shareholder interests. They will also work on addressing Nasdaq's requirements for continued listing. Sinovac's product portfolio includes several internationally recognized vaccines.
Read more →-SVA
Jan 16, 2025SINOVAC Issues Statement Regarding Privy Council Judgment BEIJING - Sinovac Biotech Ltd. (NASDAQ:SVA) ( SINOVAC or the Company ), a leading provider of biopharmaceutical products in China, today announced that the Judici
Sinovac Biotech Ltd. announced a ruling from the Judicial Committee of the Privy Council stating that the nominees proposed by a group of shareholders in the 2018 Annual General Meeting were rightly elected to lead the company. The Privy Council declared the company's Rights Agreement invalid, with the ruling set to take effect following a court order expected within a week. The outgoing board is dedicated to ensuring a smooth transition and maintaining shareholder value amidst the leadership change. Sinovac's history includes significant contributions to global vaccination efforts, particularly during the COVID-19 pandemic.
Read more →-SVA
Aug 16, 2024SINOVAC Reports Unaudited First Half of 2024 Financial Results
Sinovac Biotech Ltd. has reported its unaudited financial results for the first half of 2024, revealing a decline in revenue to $121.3 million compared to $140.4 million in the same period last year. Despite an increase in sales from Healive due to international market growth, the company's overall revenue has been negatively affected by a decrease in sales of EV71 vaccines linked to lowering birth rates in China. The firm experienced a net loss of $68.6 million in this period, contrasting sharply with a net profit of $14.0 million a year prior. Significant reductions in expenses were noted, although the company still recorded substantial losses overall.
Read more →-SVA
Apr 29, 2024SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
Sinovac Biotech Ltd. has reported its unaudited financial results for the second half of 2023, showing a revenue increase driven by influenza vaccine sales. The company filed its 2023 Annual Report on Form 20-F, revealing significant decreases in overall revenue and a higher net loss compared to the prior year. However, the firm has expanded its vaccine operations and achieved international market recognitions for its products. Strategic developments include a new production facility in Turkey and participation in a vaccine localization project in Colombia.
Read more →-SVA
Feb 21, 2024Sinovac Amends Shareholder Rights Plan
Sinovac Biotech Ltd. has announced an amendment to its shareholder rights plan, extending the expiration date from February 22, 2024, to February 22, 2025. This move aims to enhance shareholder protection and may reflect the company's strategic planning amidst its ongoing development of biopharmaceutical products. Sinovac continues to lead in vaccine production, with multiple products approved for use in various countries. The company is actively pursuing global opportunities for strategic expansion.
Read more →-SVA
Sep 11, 2023SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection Clinical trials will advance treatment of COVID-19 infection.
Sinovac Biotech Ltd. has announced the completion of phase I clinical trials for its Anti-COVID-19 Antibody SA55 Injection and has entered phase II trials. The phase II trial will involve 150 patients to assess its effectiveness in treating mild to moderate COVID-19 infections. Preliminary results are expected by the end of the year. The SA55 Injection has shown efficacy against various COVID-19 variants, and Sinovac aims to continue its contributions to global COVID-19 prevention and control.
Read more →-SVA
Aug 29, 2023Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer
Sinovac Biotech Ltd. has confirmed receipt of an unsolicited partial tender offer from Alternative Liquidity Index LP to buy up to 10 million shares at $0.03 per share. The Board of Directors is currently evaluating the offer and plans to communicate its position to shareholders within ten business days. In the meantime, shareholders are advised not to act on the tender offer. The company has a strong portfolio of vaccines and biopharmaceutical products, with international recognition.
Read more →-SVA
Aug 28, 2023Sinovac Announces Change of Legal Representative of Sinovac Beijing
Sinovac Biotech Ltd. has announced a change in the legal representative of its subsidiary, Sinovac Beijing, appointing Mr. Weidong Yin as the new legal representative and chairman. The change was made in accordance with regulatory requirements following decisions from a court in Shandong Province. Sinovac's ownership structure remains intact, with significant equity stakes held by its parent companies. The announcement reflects ongoing developments within the company's operational governance.
Read more →-SVA
Aug 15, 2023SINOVAC Reports Unaudited First Half of 2023 Financial Results
SINOVAC Biotech Ltd. released its unaudited financial results for the first half of 2023, reporting a dramatic decline in revenue to $140.4 million from $1.2 billion the previous year, attributed mainly to falling sales of its CoronaVac vaccine. The company's gross margin turned negative at 34.2%, leading to a net loss of $30 million. Despite financial struggles, SINOVAC is focusing on vaccine R&D and has seen approvals for new antibody products and established production lines for influenza and varicella vaccines. Additionally, they announced a strategic partnership to build a local vaccine facility in Colombia.
Read more →-SVA
May 1, 2023SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
Sinovac Biotech Ltd. recently filed its 2022 annual report and detailed its unaudited financial results for the second half of the year. The company experienced a significant revenue decline, primarily due to reduced sales of its COVID-19 vaccine, CoronaVac. Despite increased investments in research and development and notable achievements in vaccine approvals, the net income for 2022 saw a stark drop. Looking forward, Sinovac aims to enhance its market reach and continue developing vaccines while grappling with financial losses.
Read more →-SVA
Dec 29, 2022SINOVAC Reports Unaudited First Half of 2022 Financial Results
SINOVAC Reports Unaudited First Half of 2022 BEIJING, China, December 29, 2022 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the
Read more →-SVA
Nov 4, 2022SINOVAC Varicella Vaccine Prequalified by WHO
SINOVAC Varicella Vaccine Prequalified by WHO November 4, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organi
Read more →-SVA
Jun 8, 2022SINOVAC Polio Vaccine Prequalified by
Polio Vaccine Prequalified by WHO BEIJING, China, June 8, 2022 --SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received the World Health Organization (WHO) prequalification fo
Read more →-SVA
May 6, 2022SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act BEIJING, China, May 6, 2022 -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, is aware that the Company has been identified
Read more →-SVA
Apr 29, 2022SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F China, April 29, 2022 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2
Read more →-SVA
Feb 22, 2022Sinovac Amends Shareholder Rights Plan BEIJING
Amends Shareholder Rights Plan BEIJING, February 22, 2022 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights
Read more →-SVA
Dec 30, 2021SINOVAC Reports Unaudited First Half of 2021 Financial Results
Reports Unaudited First Half of 2021 Financial Results BEIJING, China, December 30, 2021 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial resul
Read more →-SVA
Dec 9, 2021Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment Current SINOVAC Directors Elected Properly at the 2018 Annual General Meeting The Company's Rights Agreement is Valid under Antigua Law
Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment Current SINOVAC Directors Elected Properly at the 2018 Annual General Meeting The Company's Rights Agreement is Valid under Antigua Law December 9, 2021 -- BEIJING--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("S
Read more →-SVA
Dec 3, 2021SINOVAC Beijing Settled Litigation of Its Business License and Seals BEIJING
SINOVAC Beijing Settled Litigation of Its Business License and Seals BEIJING, December 3, 2021--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced the Company's subsidiary SINOVAC Biotech Co.,
Read more →-SVA
Nov 9, 2021Preliminary Results Show SINOVAC's COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
Show SINOVAC's COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population BEIJING, China, November 9, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announc
Read more →-SVA
Jul 19, 2021SINOVAC's CoronaVac Used on Child Population in China, Good Antibody Levels Observed After Three Months Following Vaccination
SINOVAC's CoronaVac Used on Child Population in China, Good Antibody Levels Observed After Three Months Following Vaccination China, July 19, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, tod
Read more →-SVA
Jul 19, 2021SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy
Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy China, July 19, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced
Read more →-SVA
Jul 12, 2021SINOVAC Enters Into Agreement to Supply CoronaVac to
Enters Into Agreement to Supply CoronaVac to COVAX China, July 12, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it had signed an advance purchase agreement (APA) with Gav
Read more →-SVA
Jun 30, 2021The Lancet Infectious Diseases Published Data from Sinovac's Phase I/II Study, World's First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old - Co
The Lancet Infectious Diseases Published Data from Sinovac's Phase I/II Study, World's First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old is safe among the pediatric group aged 3 to 17 years old - C
Read more →-SVA
Jun 2, 2021World Health Organization Authorizes SINOVAC's CoronaVac for Emergency Use BEIJING--SINOVAC Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announ
Health Organization Authorizes SINOVAC's CoronaVac for Emergency Use BEIJING--SINOVAC Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac , an innovative, inactivated coronavirus va
Read more →-SVA
Apr 22, 2021Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F
Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual BEIJING, China, April 22, 2021 /Business Wire/ Sinovac Biotech Ltd. (NASDAQ: SVA) ( Sinovac or the Company ), a leading provider of biopharmaceutical products in China, has filed its 2020 annu
Read more →-SVA
Apr 1, 2021Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine BEIJING
Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine BEIJING, April 1, 2021--Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the third production line
Read more →-SVA
Feb 3, 2021Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China BEIJING
Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China February 3, 2021-(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has officially
Read more →-SVA
Dec 9, 2020Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine BEIJING
Sinovac Announces Product License for 23-Valent Pneumococcal Polysaccharide Vaccine BEIJING, December 9, 2020--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the
Read more →-SVA
Dec 7, 2020Sinovac Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development BEIJING
Secures Approximately $500 Million in Funding for COVID-19 Vaccine Development BEIJING, December 7, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that Sinov
Read more →-SVA
Sep 28, 2020Beijing Fourth Intermediate People's Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan BEIJING
Fourth Intermediate People's Court Issues Judgement Against Sinobioway Medicine and Mr. Aihua Pan BEIJING, September 28, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announ
Read more →-SVA
Sep 23, 2020Sinovac's Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children
Coronavac, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, for Phase I/II Clinical Trial in Adolescents and Children China, September 23, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in C
Read more →-SVA
Sep 22, 2020Sinovac Commences Phase III Clinical Trials for COVID-19 Vaccine Candidate in Turkey
Commences Phase III Clinical Trials for COVID-19 Vaccine BEIJING, China, September 22, 2020 --(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it has recently comm
Read more →-SVA
Aug 28, 2020Sinovac Reports Unaudited Second Quarter 2020 Financial Results BEIJING--( BUSINESS WIRE )-- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, ann
Sinovac Reports Unaudited Second Quarter 2020 Financial Results WIRE)-- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the second quarter ended June
Read more →-SVA
Aug 25, 2020Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation
Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation China - August 25, 2020 -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has signed two agreements in Haina
Read more →-SVA
Jul 6, 2020Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial Beijing
Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial 6, 2020 - Sinovac Biotech Ltd. ( "Sinovac" or the " Company")(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced an update to its previously
Read more →-SVA
Jun 30, 2020Sinovac Reports Unaudited First Quarter 2020 Financial Results
Reports Unaudited First Quarter 2020 Financial Results China, June 30, 2020 / Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the fi
Read more →-SVA
Jun 24, 2020Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine BEIJING - (BUSINESS WIRE) - Sinovac Biotech Ltd. ("Sinovac" or the "Company")(Nasdaq: SVA), a leading provider of biopharmaceutical products in
Sinovac Receives Approval from China for its Quadrivalent Influenza Vaccine BEIJING - (BUSINESS WIRE) - Sinovac Biotech Ltd. ("Sinovac" or the "Company")(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced the China National Medical Product
Read more →-SVA
Jun 13, 2020Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19 Beijing
Sinovac Announces Positive Preliminary Results of Phase I/II Clinical Trials for Inactivated Vaccine Candidate Against COVID-19 Beijing-June 13, 2020 - Sinovac Biotech Ltd. ("Sinovac" or the " Company")(Nasdaq: SVA), a leading provider of biopharmaceutical products in China,
Read more →-SVA
Jun 11, 2020Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III Beijing (China), Sao Paulo, (Brazil), June 11th, 2020 - Sinovac Biotech Ltd., ("Sinovac" or the "C
Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III Beijing (China), Sao Paulo, (Brazil), June 11th, 2020 - Sinovac Biotech Ltd., ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmac
Read more →-SVA
May 22, 2020Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development BEIJING
Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development BEIJING, May 22, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a transaction in wh
Read more →-SVA
May 18, 2020Sinovac Comments on SEC Findings Against Jiaqiang Chiang Li and 1Globe Capital SEC Order found Li and 1Globe Violated SEC Rules and Federal Securities Laws by Failing to Disclose Key Facts regarding their Holdings of Sin
Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital and 1Globe Violated SEC Rules and Federal Securities Laws by Failing to Disclose Key Facts regarding their Holdings of Sinovac BEIJING, May 18, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (N
Read more →-SVA
May 6, 2020Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE --- Inactivated vaccine for SARS-CoV-2 shows good safety and efficacy on Rhesus Macaques
Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE --- Inactivated vaccine for SARS-CoV-2 shows good safety and efficacy on BEIJING, China, May 6, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a le
Read more →-SVA
Apr 30, 2020Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F
Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F China, April 30, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2
Read more →-SVA
Apr 17, 2020Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING --(BUSINESS WIRE)
Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING --(BUSINESS WIRE)-- April 17, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the
Read more →-SVA
Apr 14, 2020Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19 BEIJING--(BUSINESS WIRE)
Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19 BEIJING--(BUSINESS WIRE)-- April 14, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the Company has
Read more →-SVA
Dec 27, 2019Sinovac Announces Approval of Varicella Vaccine for Prevention of Varicella-Zoster Virus (Chickenpox) in Children BEIJING
Sinovac Announces Approval of Varicella Vaccine for Prevention of Varicella-Zoster Virus (Chickenpox) in Children BEIJING, December 27, 2019--Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today anno
Read more →-SVA
Nov 15, 2019Sinovac Reports Unaudited Third Quarter 2019 Financial Results
Reports Unaudited Third Quarter 2019 Financial Results China, Novermber 15, 2019 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for th
Read more →-SVA
Aug 15, 2019Sinovac Reports Unaudited Second Quarter 2019 Financial Results
Reports Unaudited Second Quarter 2019 Financial Results China, August 15, 2019 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the
Read more →-SVA
Jul 10, 2019Sinovac Reports Unaudited First Quarter 2019 Financial Results
Sinovac Reports Unaudited First Quarter 2019 Financial Results BEIJING, China, July 10, 2019 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial res
Read more →-SVA
Apr 29, 2019Sinovac Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F
Reports Unaudited Second Half of 2018 Financial Results and Files 2018 Annual Report on Form 20-F China, April 29, 2019 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, has filed its 2018
Read more →-SVA
Apr 16, 2019Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease The Sinovac-developed sIPV demonstrates both long-term affor
Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease 16, 2019 08:00 AM Eastern Daylight Time WIRE)--Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading provider o
Read more →-SVA
Apr 12, 2019Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares April 12, 2019 05:04 PM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China,
Read more →-SVA
Mar 8, 2019Sinovac: Press Release - Sinovac Updates Exchange Mechanics Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
Sinovac: Press Release - Sinovac Updates Exchange Mechanics Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares BEIJING, - Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China
Read more →-SVA
Feb 22, 2019Sinovac Determines Trigger Event Occurred Under Rights Agreement Sinovac Board of Directors Determines Certain Collaborating Shareholders Became Acquiring Persons, Voiding their Preferred Share Purchase Rights; Valid Pre
Sinovac Determines Trigger Event Occurred Under Rights Agreement Beijing--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its Board of Directors (the "Board") det
Read more →-SVA
Dec 19, 2018Sinovac Comments on Antigua and Barbuda Court Decision Denying 1Globe Capital's Claim; Current Board Was Validly Elected at Annual General Meeting
Sinovac Comments on Antigua and Barbuda Court Decision Denying 1Globe Capital's Claim; Current Board Was Validly Elected at Annual General Meeting December 19, 2018 04:45 PM Eastern Standard Time WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading
Read more →-SVA
Dec 12, 2018Haidian District People's Court in Beijing Issues Injunction Order Restraining Aihua Pan from Using Business License and Corporate Seal of Sinovac Beijing Interim Injunction Order Restrains Mr. Aihua Pan from using busin
Haidian District People's Court in Beijing Issues Injunction Order Restraining Aihua Pan from Using Business License and Corporate Seal of Sinovac Beijing Injunction Order Restrains Mr. Aihua Pan from using business license and corporate seal of Sinovac Beijing obtained with d
Read more →-SVA
Nov 28, 2018Hong Kong High Court Issues Declaratory Orders and Permanent Injunctive Relief in Favor of Sinovac's Biotech Ltd. Senior Management Permanent Injunction Restrains Mr. Li and Mr. Cao from Purporting to Act as or Take Any
Hong Kong High Court Issues Declaratory Orders and Permanent Injunctive Relief in Favor of Sinovac's Biotech Ltd. Permanent Injunction Restrains Mr. Li and Mr. Cao from Purporting to Act as or Take Any Actions as Directors of Sinovac HK or its subsidiaries BEIJING, Nov. 28,
Read more →-SVA
Nov 8, 2018Sinovac Reports Unaudited First Half of 2018 Financial Results
Reports Unaudited First Half of 2018 Financial Results China, November 8, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six
Read more →-SVA
Oct 22, 2018Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures
Sinovac Granted Interim Injunctive Relief Regarding Filings Bearing a Falsified Company Seal and Forged Board Member Signatures October 22, 2018 06:12 AM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Senior management of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the
Read more →-SVA
Oct 17, 2018U.S. District Court in Massachusetts Denies 1Globe's Motion for Preliminary Injunction to Enjoin Sinovac's Issuance of Shares BEIJING
U.S. District Court in Massachusetts Denies 1Globe's Motion for Preliminary Injunction to Enjoin Sinovac's BEIJING, October 17, 2018 -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced
Read more →-SVA
Oct 15, 2018Sinovac Commences Legal Proceedings to Nullify Filings Bearing a Falsified Company Seal and Forged Board Member Signatures
Sinovac Commences Legal Proceedings to Nullify Filings Bearing a Falsified Company Seal and Forged Board Member Signatures October 15, 2018 08:02 PM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Senior management of Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Comp
Read more →-SVA
Oct 9, 2018Sinovac Comments on Unauthorized Use of Falsified Sinovac Hong Kong's Company Seal and Subsidiary Board Member Signatures
Comments on Unauthorized Use of Falsified Sinovac Hong Kong's Company Seal and Subsidiary Board Member Signatures October 09, 2018 11:51 PM Eastern Daylight Time BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), became aware Monday Octo
Read more →-SVA
Sep 17, 2018DOJ Closes Investigation of Sinovac BEIJING
DOJ Closes Investigation of BEIJING, Sept. 17, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the U.S. Department of Justice ("DOJ") has closed its investigat
Read more →-SVA
Aug 20, 2018SEC Concludes Investigation of Sinovac BEIJING
Investigation of Sinovac BEIJING, August 20, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that the U.S. Securities and Exchange Commission ("SEC") has concluded
Read more →-SVA
Jul 3, 2018Sinovac Raises $86.73 Million Through Private Placement Transaction Vivo Capital and Advantech Capital Each Hold an Approximately 8.3% Stake in Sinovac After the Private Placement Transaction Proceeds Will Be Used to Fun
Raises $86.73 Million Through Private Placement Transaction BEIJING, July 3, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has completed a private placeme
Read more →-SVA
Jun 26, 2018Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court The summary judgment motion asks the Delaware Court to ascertain whether a trigger event under its Rights Agreement has occurred Th
Sinovac Files Motion for Summary Judgment on Rights Agreement in Delaware Chancery Court BEIJING, June 26, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it
Read more →-SVA
May 11, 2018Sinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Second Half, Audited Full Year 2017 Financial Results BEIJING
Sinovac Files 2017 Annual Report on Form 20-F and Reports Unaudited Audited Full Year 2017 Financial Results BEIJING, May 11, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announ
Read more →-SVA
May 8, 2018Sinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing Actions of Aihua Pan continue to harm the Company's shareholders and cu
Sinovac Forced to Temporarily Suspend Hepatitis A Vaccine Production Line Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing Actions of Aihua Pan continue to harm the Company's shareholders and customers BEIJING, May 8, 2018 /PRNewswire/ -- Sinovac Bio
Read more →-SVA
May 1, 2018Sinovac Forced to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing BEIJING
to Temporarily Suspend Flu Vaccine Production Due to Disruptive Actions taken by Minority Shareholder of Sinovac Beijing May 1, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, toda
Read more →-SVA
Apr 30, 2018Sinovac Temporarily Blocks Access to Its Websites BEIJING
Sinovac Temporarily Blocks Access to Its Websites BEIJING, April 30, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced that Aihua Pan, the Chairman of the Board of
Read more →-SVA
Apr 27, 2018Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing BEIJING
Sinovac to Delay Filing of 2017 Annual Report on Form 20-F Following Actions Taken by the Minority Shareholder of Sinovac Beijing BEIJING, April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical p
Read more →-SVA
Apr 27, 2018Sinovac Enters into Amendment to Amalgamation Agreement for Going-Private Transaction BEIJING
Enters into Amendment to Amalgamation Agreement Going-Private Transaction BEIJING, April 27, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that on April 26, 2018
Read more →-SVA
Apr 23, 2018Sinovac Resumes Production and Operation at Sinovac Beijing's Quality Assurance Department BEIJING
Sinovac Resumes Production and Operation at Sinovac Beijing's Quality Assurance Department BEIJING, April 23, 2018 -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced that hepatitis A
Read more →-SVA
Apr 19, 2018Sinovac Announces Preliminary Results of Phase III Trial on sIPV BEIJING
Sinovac Announces Preliminary Results of Phase III Trial on sIPV BEIJING, April 19, 2018 -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical
Read more →-SVA
Apr 18, 2018Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd. - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsi
Sinovac Sets the Record Straight Regarding False Statements by Shandong Sinobioway Biomedicine Co., Ltd. - Expresses Concern over Aggressive and Damaging Actions Taken by a Minority Shareholder of Sinovac's Beijing Subsidiary - - Reaffirms Commitment to Take All Appropriate A
Read more →-SVA
Mar 15, 2018Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties BEIJING
Sinovac Sets the Record Straight Regarding False Statements by Unauthorized Third Parties BEIJING, March 15, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today responded to pub
Read more →-SVA
Mar 6, 2018Sinovac Announces Re-Election of All Directors at Annual General Meeting Asks Delaware Court of Chancery to Determine Whether Dissident Shareholders Triggered Sinovac's Shareholder Rights Plan Board Approves Extension of
Sinovac Announces Re-Election of All Directors at Annual General Meeting Asks Delaware Court of Chancery to Determine Whether Dissident Shareholders Triggered Sinovac's Shareholder Rights Plan Board Approves Extension of Shareholder Rights Plan to March 27, 2019 Company Fil
Read more →-SVA
Feb 7, 2018Sinovac Holds 2017 Annual General Meeting of Shareholders BEIJING
Sinovac Holds 2017 Annual General Meeting BEIJING, February 7, 2018 / PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it held its 2017 Annual General Meeting of Shar
Read more →-SVA
Dec 22, 2017Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization BEIJING
Biotech Receives Positive Decision on its Hepatitis A Vaccine from World Health Organization BEIJING, Dec. 22, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced today that
Read more →-SVA
Dec 1, 2017Sinovac Reports Unaudited First Half of 2017 Financial Results
Sinovac Reports Unaudited First Half of 2017 Financial Results China, December 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it reported its unaudited fin
Read more →-SVA
Dec 1, 2017Sinovac Biotech Cures Nasdaq Filing Deficiency BEIJING
Sinovac Biotech Cures Nasdaq Filing Deficiency BEIJING, December 1, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced today that it has received a Nasdaq Staff letter indica
Read more →-SVA
Nov 30, 2017Sinovac Biotech Announces Update on Nasdaq Matters BEIJING
Sinovac Biotech Announces Update on Nasdaq BEIJING, November 30, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced today that the Nasdaq Hearings Panel (the "Panel") granted
Read more →-SVA
Nov 22, 2017Sinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results
Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results China, November 22, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced toda
Read more →-SVA
Nov 8, 2017Sinovac Biotech Announces Request Hearing before Nasdaq Hearings Panel BEIJING
Sinovac Biotech Announces Request Hearing before Nasdaq Hearings Panel BEIJING, November 8, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA) (the "Company" or "Sinovac"), a leading provider of biopharmaceutical products in China, announced today that the Company submit
Read more →-SVA
Nov 3, 2017Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq BEIJING
Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq BEIJING, November 3, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)("Sinovac"), a leading provider of biopharmaceutical products in China, announced today that on November 1, 2017, the Co
Read more →-SVA
Aug 14, 2017Sinovac Biotech Announces Certain Updates Relating to Delayed Filing of Annual Report on Form 20-F BEIJING
Sinovac Biotech Announces Certain Updates Relating to Delayed Filing of Annual BEIJING, Aug. 14, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that The NASDAQ St
Read more →-SVA
Jun 26, 2017Sinovac Biotech Ltd. Enters into Definitive Agreement for Going-Private Transaction BEIJING
Sinovac Biotech Ltd. Enters into Definitive Agreement for Going-Private Transaction BEIJING, June 26, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it has e
Read more →-SVA
May 16, 2017Sinovac Biotech Announces Receipt of NASDAQ Letter and Delayed Filing of Annual Report on Form 20-F BEIJING
Sinovac Biotech Announces Receipt of and Delayed Filing of Annual Report on May 16, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA)("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it is delaying its Annual Re
Read more →-SVA
Feb 8, 2017Sinovac Reports Unaudited Third Quarter 2016 Financial Results BEIJING
Reports Unaudited Third Quarter 2016 Financial Results Nov. 28, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter ended September 30, 2016. Weidong Yin, Chairman, Pres
Read more →-SVA
Dec 23, 2016Sinovac Responds to Recent Report
Sinovac Responds to Recent Report BEIJING, China, December 23, 2016 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today responded to a recent report regarding the allegations raised in a research report by Geoinvesting. Sino
Read more →-SVA
Nov 7, 2016Sinovac Announces Results of 2016 Annual General Meeting of Shareholders BEIJING
Sinovac Announces Results of 2016 Annual General Meeting of Shareholders BEIJING, November 7, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2016 Annual General Me
Read more →-SVA
Oct 19, 2016Sinovac Product Pipeline News
Sinovac Product Pipeline News BEIJING, China, October 19, 2016 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today provided an update on the Company's Sabin-inactivated polio vaccine (sIPV)-The Company initiated the phase I
Read more →-SVA
Sep 30, 2016Sinovac Schedules 2016 Annual Meeting of Shareholders BEIJING
Sinovac Schedules 2016 Annual Meeting Sept. 30, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2016 Annual Meeting of Shareholders on Monday, November 7, 2016 at 9:00 a.m.
Read more →-SVA
Aug 23, 2016Sinovac Reports Unaudited Second Quarter 2016 Financial Results BEIJING
Reports Unaudited Second Quarter 2016 Financial Results August 23, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter ended June 30, 2016. Weidong Yin, Chairman, Presi
Read more →-SVA
May 26, 2016Sinovac Reports Unaudited First Quarter 2016 Financial Results BEIJING
Sinovac Reports Unaudited First Quarter 2016 Financial Results BEIJING, May 26, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter ended March 31, 2016. First Quarter
Read more →-SVA
Apr 14, 2016Sinovac Special Committee Engages Financial and Legal Advisors BEIJING
Sinovac Special Committee Engages Financial and Legal Advisors BEIJING, April 14, 2016 -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the independent special committee of the Compan
Read more →-SVA
Mar 28, 2016Sinovac Adopts Shareholder Rights Plan and Declares Dividend Distribution of Preferred Share Purchase Rights BEIJING
Adopts Shareholder Rights Plan and Declares Dividend Distribution of Preferred Share Purchase Rights BEIJING, March 28, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announ
Read more →-SVA
Feb 4, 2016Sinovac Announces Receipt of Competing Non-Binding "Going Private" Proposal BEIJING
Receipt of Competing Non-Binding "Going Private" Proposal BEIJING, February 4, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the special committee of its boa
Read more →-SVA
Feb 1, 2016Sinovac Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company and Formation of Independent Special Committee BEIJING
Receipt of a Preliminary Non-Binding Proposal to Acquire the Company and Formation of Independent Special Committee BEIJING, February 1, 2016 /PRNewswire/ -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in Ch
Read more →-SVA
Jan 28, 2016Sinovac Biotech Announces Issuance of GMP Certificate for EV71 Vaccine BEIJING
Sinovac Biotech Announces Issuance of GMP Certificate for EV71 Vaccine BEIJING, January 28, 2016 - Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that the China Food and Drug Administration ("CFDA") has issued the Good M
Read more →-SVA
Jan 5, 2016Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate BEIJING
Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate BEIJING, December 10, 2015 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on
Read more →-SVA
Nov 12, 2015Sinovac Reports Unaudited Third Quarter Financial Results -- Conference call scheduled for Thursday
Sinovac Reports Unaudited Third Quarter -- Conference call scheduled for Thursday, November 12, 2015 at 8:00 AM ET -- BEIJING, November 11, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its
Read more →-SVA
Nov 2, 2015Sinovac to Host Conference Call to Report Third Quarter 2015 Unaudited Financial Results BEIJING
Sinovac to Host Conference Call to Report Third Quarter 2015 Unaudited Financial Results BEIJING, Nov. 2, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited fina
Read more →-SVA
Oct 26, 2015Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate BEIJING
Receives Clinical Trial Approval for Varicella Vaccine Candidate BEIJING, Oct. 26, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received appr
Read more →-SVA
Sep 10, 2015Sinovac to Participate in Morgan Stanley Global Healthcare Conference BEIJING
Sinovac to Participate in Morgan Stanley Global Healthcare Conference BEIJING, September 10, 2015 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will participate the Morgan Stanley
Read more →-SVA
Aug 4, 2015Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results Date: 2015-08-04 Pageview: 1308 BEIJING
Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results BEIJING, August 4, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial res
Read more →-SVA
May 15, 2015Sinovac Reports Unaudited First Quarter 2015 Financial Results - Conference call scheduled for
Sinovac Reports Unaudited First Quarter 2015 Financial Results - Conference call scheduled for May 15, 2015 at 8:00 a.m. ET - BEIJING, May 14, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced its unau
Read more →-SVA
May 14, 2015Sinovac Receives Site Inspection Notification for EV71 Vaccine Production Facilities BEIJING
Sinovac Receives Site Inspection Notification for EV71 Vaccine Production Facilities BEIJING, May 14, 2014 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company received site inspection notification f
Read more →-SVA
May 12, 2015Sinovac to Participate in UBS Global Healthcare Conference BEIJING
Sinovac to Participate in UBS Global Healthcare Conference BEIJING, May 12, 2015 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will present at the UBS Global Healthcare Conference
Read more →-SVA
May 7, 2015Sinovac to Host Conference Call to Report First Quarter 2015 Unaudited Financial Results BEIJING
Sinovac to Host Conference Call to Report First Quarter 2015 Unaudited Financial Results BEIJING, May 7, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results
Read more →-SVA
Apr 29, 2015Sinovac Files 2014 Annual Report on Form 20-F BEIJING
Sinovac Files 2014 Annual Report on Form BEIJING, April 29, 2015 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it
Read more →-SVA
Apr 20, 2015Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results - Conference call scheduled for
Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 - Conference call scheduled for April 20, 2015 at 8:00 a.m. ET - BEIJING, April 20, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced its unau
Read more →-SVA
Apr 15, 2015Sinovac Provides Updates on Pipeline Vaccines BEIJING
Provides Updates on Pipeline Vaccines March 17, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today provided updates on the Company's pipeline vaccines. vaccine. The Company submitted supplementary documentation to
Read more →-SVA
Nov 17, 2014Sinovac to Participate in Upcoming Investor Conferences BEIJING
to Participate in Upcoming Investor Conferences BEIJING, September 2, 2014 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will participate in the following investor conferences in S
Read more →-SVA
Aug 19, 2014Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program BEIJING
Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded Immunization Program 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the
Read more →-SVA
Aug 15, 2014Sinovac Reports Unaudited Second Quarter Financial Results -- Conference call scheduled for Friday
Sinovac Reports Unaudited Second Quarter Financial Results -- Conference call scheduled for Friday, August 15, 2014 at BEIJING, Aug.14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaud
Read more →-SVA
Jul 14, 2014Sinovac Schedules 2014 Annual Meeting of Shareholders BEIJING
Schedules 2014 Annual Meeting of Shareholders 2014 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time
Read more →-SVA
Jun 25, 2014Sinovac Announces Favorable Reduction in Value Added Tax Rate BEIJING
Announces Favorable Reduction in Value Added Tax Rate 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT") rate applied to the sales of Sinovac's vaccine products
Read more →-SVA
Jun 24, 2014Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) -- Collaborating with World Health Organization and Intravacc to Develop sIPV in line with m
Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin Inactivated Polio Vaccine (sIPV) Collaborating with World Health Organization and Intravacc to Develop sIPV in line with mission to secure a lasting polio-free world, free of all paralytic po
Read more →-SVA
Apr 16, 2014Sinovac Files 2013 Annual Report on Form 20-F BEIJING
Files 2013 Annual Report on Form 20-F April 16, 2014 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has filed it
Read more →-SVA
Mar 24, 2014Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine against Avian Influenza A(H7N9) Virus - -Preclinical development completed for H7N9 vaccine candidates that addresses significant unmet medic
Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine against Avian Influenza A(H7N9) Virus -Preclinical development completed for H7N9 vaccine candidates that addresses significant BEIJING, January 29, 2014-Sinovac Biotech Ltd. (Nasdaq:SVA), a leadi
Read more →-SVA
Jan 27, 2014Sinovac Holds 2013 Annual General Meeting of Shareholders BEIJING
Sinovac Holds 2013 Annual General Meeting of Shareholders BEIJING, Aug. 21, 2013 /PRNewswire/ - Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it held its 2013 Annual General Meeting of Shareholders on Wednesday, Au
Read more →-SVA
Aug 16, 2013Sinovac Schedules 2013 Annual Meeting of Shareholders BEIJING
Sinovac Schedules 2013 Annual Meeting of Shareholders BEIJING, July 19, 2013 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2013 Annual Meeting of Shareholders on Wednesday, August 21, 20
Read more →-SVA
May 28, 2013Sinovac Reports Unaudited First Quarter 2013 Financial Results -Conference call scheduled for Tuesday
Sinovac Reports Unaudited First Quarter 2013 Financial Results -Conference call scheduled for Tuesday, May 28, 2013 at 8:00 AM EDT - BEIJING, May 28, 2013 /PRNewswire/ - Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today it
Read more →-SVA
May 24, 2013Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines Beijing
Obtains China GMP Certificate Under the New GMP Guidelines Beijing - May 24, 2013 - Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Cer
Read more →-SVA
May 15, 2013SINOVAC APPOINTS ERNST & YOUNG HUA MING LLP CHINA AS EXTERNAL AUDITOR Beijing
SINOVAC APPOINTS ERNST & YOUNG HUA MING LLP CHINA AS EXTERNAL AUDITOR Beijing- May 15, 2013 - Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, has appointed China-based Ernst & Young Hua Ming LLP as its registered independent publ
Read more →-SVA
May 3, 2013Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease -- Unblinded Phase III Preliminary Results Demonstrate Vaccine Efficacy Rate of 9
Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease -- Unblinded Phase III Preliminary Results Demonstrate Vaccine Efficacy Rate of 95.4% BEIJING, March 14, 2013 /PRNewswire/ -- Sinovac Bio
Read more →-SVA
Nov 15, 2012Sinovac Reports Unaudited Third Quarter 2012 Financial Results - Conference call scheduled for Thursday
Sinovac Reports Unaudited Third Quarter 2012 Financial Results - Conference call scheduled for Thursday, November 15, 2012 at 8:00 AM EST- Beijing - November 15, 2012 - Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, announced today its unaudited
Read more →-SVA
Sep 28, 2012Sinovac Reports Unaudited Second Quarter 2012 Financial Results - Conference call scheduled for Wednesday
Sinovac Reports Unaudited Second Quarter 2012 Financial Results - Conference call scheduled for Wednesday, August 15, 2012 at BEIJING, Aug. 15, 2012 /PRNewswire-Asia/ - Sinovac Biotech Ltd. (the company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China
Read more →-SVA
Sep 26, 2012Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it has bee
Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and
Read more →-SVA
Sep 26, 2012Sinovac Holds 2012 Annual General Meeting of Shareholders BEIJING
Sinovac Holds 2012 Annual General Meeting BEIJING, Aug. 23, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it held its 2012 Annual General Meeting of Shareholders on Wednesday, August 22, 20
Read more →-SVA
Jul 16, 2012Sinovac Schedules 2012 Annual Meeting of Shareholders BEIJING
Sinovac Schedules 2012 Annual Meeting BEIJING, July 16, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2012 Annual Meeting of Shareholders on Wednesday, August 22, 2012 at 9:00
Read more →-SVA
May 15, 2012Sinovac Reports Unaudited First Quarter 2012 Financial Results - Conference call scheduled for Tuesday
Sinovac Reports Unaudited First Quarter 2012 Financial Results - Conference call scheduled for Tuesday, May 15, 2012 at 8:00 AM EDT - Beijing - May 15, 2012 - Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its
Read more →-SVA
May 14, 2012Sinovac Names Danny Chung Chief Financial Officer Beijing
Chung Chief Financial Officer Beijing - May 14, 2012 - Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, has appointed Mr. Danny Chung as Chief Financial Officer, effective immediately. Ms. Nan Wang, who has served as interim Chief
Read more →-SVA
Mar 29, 2012Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2011 Financial Results - Conference call scheduled for Thursday
Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2011 Financial Results - Conference call scheduled for Thursday, March 29, 2012 at BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical produ
Read more →-SVA
Mar 29, 2012Sinovac Announces Director Appointment BEIJING
Sinovac Announces Director Appointment BEIJING, March 29, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the appointment of Mr. Meng Mei as an independent director to fill the vacancy cre
Read more →-SVA
Jan 24, 2012Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement Press Release: Sinovac Biotech Co., Ltd. - Tue
Sinovac Receives Nasdaq Deficiency Letter Regarding Audit Committee Requirement Press Release: Sinovac Biotech Co., Ltd. - Tue, Jan 24, 2012 4:05 PM EST BEIJING, Jan. 24, 2012 /PRNewswire-Asia/ - Sinovac Biotech Ltd. (Nasdaq: SVA - News), a leading provider of vaccines in Ch
Read more →-SVA
Jan 4, 2012Unassociated Document Sinovac Announces Resignation of Chup Hung Mok from Board of Directors Press Release: Sinovac Biotech Ltd. - Wed
Sinovac Announces Resignation of Chup Hung Mok from Board of Directors Press Release: Sinovac Biotech Ltd. - Wed, Jan 4, 2012 8:00 AM EST BEIJING , Jan. 4, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA - News), a leading provider of vaccines in China , today annou
Read more →-SVA
Dec 8, 2011Unassociated Document /CORRECTION/-Sinovac Biotech Ltd. In the news release, " Sinovac Reports Unaudited Third Quarter 2011 Financial Results" with financial tables, issued on
/CORRECTION/-Sinovac Biotech Ltd. In the news release, " Sinovac Reports Unaudited Third Quarter 2011 Financial Results" with financial tables, issued on November 14, 2011 by Sinovac Biotech Ltd. over PR Newswire Asia, we are advised by the Company that the third sentence of the
Read more →-SVA
Aug 12, 2011Sinovac Reports Unaudited Second Quarter 2011 Financial Results - Conference call scheduled for Friday
Sinovac Reports Unaudited Second Quarter 2011 Financial Results - Conference call scheduled for Friday, August 12, 2011 at 8:00 AM EDT - Beijing - August 12, 2011 - Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today it
Read more →-SVA
Aug 5, 2011Sinovac Announces Management Changes -Chief Financial Officer Resigns - -Vice President of Sinovac Named Interim Chief Financial Officer - BEIJING
Sinovac Announces Management Changes -Chief Financial Officer Resigns - -Vice President of Sinovac Named Interim Chief Financial Officer - BEIJING, August 5, 2011 -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today
Read more →-SVA
Jul 20, 2011Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) - Unblinded Results for Children and Infant Groups Show Good Safety Profile Following Previously
Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD) - Unblinded Results for Children and Infant Groups Show Good Safety Profile Following Previously Announced Positive Adult Group Results - BEIJING, May 25
Read more →-SVA
Jul 14, 2011Sinovac Holds 2011 Annual Shareholders Meeting Press Release Source: Sinovac Biotech Ltd. On Thursday
Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materia
Read more →-SVA
Jul 11, 2011Sinovac Reports Unaudited First Quarter 2011 Financial Results - Conference call scheduled for Friday
Sinovac Reports Unaudited First Quarter 2011 Financial Results - Conference call scheduled for Friday, May 13, 2011 at 8:00 AM EDT - BEIJING, May 13, 2011 /PRNewswire-Asia/ - Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announce
Read more →-SVA
Apr 18, 2011Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group Unblinded Results Show Good Safety Profile and Preliminary Immunogenicity Source: Sinovac Biotech Ltd. On Thursday
Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group Unblinded Results Show Good Safety Profile and Preliminary Immunogenicity Source: Sinovac Biotech Ltd. On Thursday March 10, 2011, 8:00 am EST BEIJING, March 10, 2011 /PRNewswir
Read more →-SVA
Apr 18, 2011Sinovac Biotech Files Clinical Trial Applications with SFDA for its Proprietary Pneumococcal Polysaccharides Vaccines (PPV) -Completes Pre-Clinical Studies- Source: Sinovac Biotech Ltd. On Monday
Sinovac Biotech Files Clinical Trial Applications with SFDA for its Proprietary Pneumococcal Polysaccharides Vaccines (PPV) -Completes Pre-Clinical Studies- Source: Sinovac Biotech Ltd. On Monday January 31, 2011, 8:00 am EST BEIJING, Jan. 31, 2011 /PRNewswire-Asia/ -- Sinovac
Read more →-SVA
Apr 18, 2011Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV) -Completes Pre-Clinical Studies- Source: Sinovac Biotech Ltd. On Thursday
Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV) -Completes Pre-Clinical Studies- Source: Sinovac Biotech Ltd. On Thursday March 3, 2011, 8:00 am EST BEIJING, March 3, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA
Read more →-SVA
Mar 31, 2011Sinovac Reports Fourth Quarter and Full Year 2010 Financial Results - Conference call scheduled for Thursday
Sinovac Reports Fourth Quarter and Full Year 2010 Financial Results - Conference call scheduled for Thursday, March 31, 2011 at 8:00 AM EDT - Beijing - March 31, 2011 - Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced toda
Read more →-SVA
Jan 6, 2011Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range BEIJING
Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range BEIJING, Jan. 6, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today its preliminary unaudited sales range for the fourth q
Read more →-SVA
Dec 28, 2010Sinovac Receives SFDA Approval to Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine BEIJING
Sinovac Receives SFDA Approval to Commence Clinical Trials For Inactivated Enterovirus Type 71 Vaccine BEIJING, December 28, 2010 /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it received app
Read more →-SVA
Nov 15, 2010Sinovac Reports Unaudited Third Quarter 2010 Financial Results - Conference call scheduled for Monday
Reports Unaudited Third Quarter 2010 Financial Results Conference call scheduled for Monday, November 15, 2010 at 8:00 AM EST Beijing November 15, 2010 Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited
Read more →-SVA
Oct 24, 2010Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations Press Release Source: Sinovac Biotech Ltd. On Sunday
Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Press Release Source: Sinovac Biotech Ltd. On Sunday October 24, 2010, 5:00 pm /PRNewswire-Asia-FirstCall/ Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of b
Read more →-SVA
Aug 16, 2010Sinovac Reports Unaudited Second Quarter 2010 Financial Results - Conference call scheduled for Monday
Reports Unaudited Second Quarter 2010 Financial Results Conference call scheduled for Monday, August 16, 2010 at 8:00 AM EDT August 16, 2010 Sinovac Biotech Ltd. (NASDAQ: SVA), a leading China-based vaccine manufacturer, announced today its unaudited financial results for the
Read more →-SVA
Jul 15, 2010Sinovac Holds 2010 Annual Meeting of Shareholders Beijing
Sinovac Holds 2010 Annual Meeting of Shareholders 2010 Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it held its 2010 Annual Meeting of Shareholders on Thursday, July 15, 2010 at 9:00 a.m. Beijing Time. The re
Read more →-SVA
Jul 1, 2010IMPORTANT REMINDER
have previously mailed to you proxy materials relating to the Annual Meeting of Shareholders scheduled to be held on Thursday, July 15, 2010. to our latest records, we have not received your proxy card for this important meeting. Regardless of the number of shares you own, it
Read more →-SVA
Jun 18, 2010Sinovac Schedules 2010 Annual Meeting of Shareholders Beijing
Sinovac Schedules 2010 Annual Meeting of Shareholders 2010 Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2010 Annual Meeting of Shareholders on Thursday, July 15, 2010 at 9:00 a.m. Beijing Time
Read more →-SVA
May 13, 2010Sinovac Reports Unaudited First Quarter 2010 Financial Results - Conference call scheduled for Thursday
Sinovac Reports Unaudited First Quarter 2010 Financial Results Conference call scheduled for Thursday, May 13, 2010 at 8:00 PM EDT May 13, 2010 Sinovac Biotech Ltd. (NASDAQ: China-based vaccine manufacturer, announced today its unaudited financial results for the three-month p
Read more →-SVA
Apr 6, 2010Sinovac Reports Unaudited Fourth Quarter and Preliminary Full Year 2009 Record Financial Results - Conference call scheduled Tuesday
Reports Unaudited Fourth Quarter and Preliminary Full Year 2009 Record Conference call scheduled Tuesday, April 6, 2010 at 9:00 a.m. EDT - Provides full year 2010 sales guidance of $67.1 million to $72.5 million - /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading
Read more →-SVA
Jan 20, 2010English Translation Equity Joint Venture Contract for the establishment of Sinovac (Dalian) Vaccine Technology Co., Ltd. i Table of Contents Chapter I The Parties 1 Chapter II Establishment of Joint Venture 1 Chapter III
(Dalian) Vaccine Technology Co., Ltd. Chapter I The Parties 1 Chapter II Establishment of Joint Venture 1 Chapter III Purpose, Business Scope and Size 2 Chapter IV Aggregate Investment and Registered Capital 2 Chapter V Contribution Proportion and Deadline of the Parties 2 Chapt
Read more →-SVA
Nov 27, 2009Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities -Sinovac to Own 55% in Joint Venture by Year End 2010- BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (
Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities -Sinovac to Own 55% in Joint Venture by Year BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announ
Read more →-SVA
Nov 18, 2009SINOVAC BIOTECH LTD. CONSOLIDATED FINANCIAL STATEMENTS (Expressed in U.S. Dollars) (Unaudited) September 30 , 2009 Index Consolidated Balance Sheets Consolidated Statement of Changes in Stockholders Equity Consolidated S
SINOVAC BIOTECH LTD. CONSOLIDATED FINANCIAL Index Consolidated Balance Consolidated Statement of Changes in Stockholders Equity Consolidated Statements of Income and Comprehensive Income Consolidated Statements Notes to Consolidated Financial Statements SINOVAC BIOTECH
Read more →-SVA
Nov 16, 2009Sinovac Reports Unaudited Third Quarter 2009 Financial Results - Conference call scheduled Monday
Sinovac Reports Unaudited Third Quarter 2009 Financial Results call scheduled Monday, November 16, 2009 at 9:00 a.m. ET - /PRNewswire-Asia/ Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today its unaudited financial results for the
Read more →-SVA
Nov 4, 2009Sinovac to Transfer Stock Exchange Listing to NASDAQ Global Market BEIJING, Nov. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that i
Sinovac to Transfer Stock Exchange Listing to NASDAQ Global Market BEIJING, Nov. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it will voluntarily transfer its stock exchange listing from
Read more →-SVA
Sep 30, 2009I. SINOVAC REPORTS UNAUDITED SECOND QUARTER 2009 FINANCIAL RESULTS - Conference call scheduled Wednesday
BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today its unaudited financial results for the three-month and six- month periods ended June 30, 2009. Financial Highlights -- Sales for t
Read more →-SVA
Sep 29, 2009Sinovac Reports Unaudited First Quarter 2009 Financial Results - Conference call scheduled Friday
Sinovac Reports Unaudited First Quarter 2009 Financial Results - Conference call scheduled Friday, May 15, 2009 at 9:00 a.m. ET- - Reaffirmation of 2009 sales projection to be $55 million to $60 million- BEIJING, May 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA
Read more →-SVA
Sep 28, 2009Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine BEIJING, Sept. 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that the f
Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine BEIJING, Sept. 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that the first lot of PANFLU.1, its H1N1 vaccine, has passed the lot
Read more →-SVA
Sep 28, 2009Sinovac Obtains Production License for H1N1 Vaccine BEIJING, Sept. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the State Food a
Sinovac Obtains Production License for H1N1 Vaccine BEIJING, Sept. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the State Food and Drug Administration (SFDA) has approved the registration
Read more →-SVA
Sep 28, 2009Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea Clarifies Details of Agreement with Boryung BEIJING, Sept. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a lea
Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea Clarifies Details of Agreement with Boryung BEIJING, Sept. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, anno
Read more →-SVA
Sep 28, 2009Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, announced today t
Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac's H1N1 vaccine has passed the experts evaluatio
Read more →-SVA
Sep 28, 2009Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens BEIJING, Aug. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical
Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens BEIJING, Aug. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Beijing Public
Read more →-SVA
Sep 22, 2009Sinovac to Present at 2009 UBS Global Life Sciences Conference BEIJING, Sept. 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr.
Sinovac to Present at 2009 UBS Global Life Sciences Conference BEIJING, Sept. 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Weidong Yin, Chairman, President & CEO, will present at the
Read more →-SVA
Sep 15, 2009Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government BEIJING, Sept. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced t
Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government BEIJING, Sept. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Ministry of Industry and Information Technolo
Read more →-SVA
Aug 27, 2009Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1) BEIJING, July 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, today annou
Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1) BEIJING, July 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, today announced that it has initiated dosing today in its clinical tri
Read more →-SVA
Aug 27, 2009China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation Emphasized Importance of Vaccine Production BEIJING, June 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a le
China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation Emphasized Importance of Vaccine Production BEIJING, June 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announc
Read more →-SVA
Aug 27, 2009Sinovac Begins the Production of Influenza A (H1N1) Vaccine On Monday
Sinovac Begins the Production of Influenza A (H1N1) Vaccine BEIJING, June 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it begins the production of a vaccine against influenza A (H1N1) vi
Read more →-SVA
Aug 27, 2009Sinovac Schedules 2008 Annual General Meeting BEIJING, June 10 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2008
Sinovac Schedules 2008 Annual General Meeting BEIJING, June 10 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2008 Annual General Meeting on Thursday, July 16, 2009 at 9:00
Read more →-SVA
Aug 27, 2009Sinovac Receives China's First Influenza A (H1N1) Vaccine Order BEIJING, June 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that the
Sinovac Receives China's First Influenza A (H1N1) Vaccine Order BEIJING, June 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that the Company received the first order in China to supply its in
Read more →-SVA
Aug 27, 2009SINOVAC RECEIVES REVISED APPROVALS FOR PANFLU Extension of Eligible Age Group Enables Sinovac to Cover Larger Part of Population Increased Panflu Dosage to 1mL per Vial Expands Filling and Packaging Capacity BEIJING, Jun
SINOVAC RECEIVES REVISED APPROVALS FOR PANFLU Extension of Eligible Age Group Enables Sinovac to Cover Larger Part of Population Increased Panflu Dosage to 1mL per Vial Expands Filling and Packaging Capacity BEIJING, June 29 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
Read more →-SVA
Aug 27, 2009Sinovac Adjourns 2008 Annual General Meeting BEIJING, July 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that its Annual General Mee
Sinovac Adjourns 2008 Annual General Meeting BEIJING, July 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, announced today that its Annual General Meeting originally scheduled for July 16, 2009 has been adjour
Read more →-SVA
Aug 27, 2009SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in Chi
SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 3 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of its A/H1N1
Read more →-SVA
Aug 27, 2009REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccin
REVISED: SINOVAC PROVIDES UPDATE ON CLINICAL TRIAL FOR H1N1 VACCINE TRIALS -H1N1 Vaccine Shows Good Safety Profile- BEIJING, Aug. 4 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE AMEX: SVA), a leading provider of vaccines in China, announced today that the clinical trial of it
Read more →-SVA
Aug 19, 2009Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that i
Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results BEIJING, Aug. 11 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Wednesday, August 19, 2009
Read more →-SVA
Aug 17, 2009SINOVAC REPORTS TOP-LINE PRELIMINARY RESULTS OF H1N1 VACCINE CLINICAL TRIALS - Results Show Good Safety Profile and Immunogenicity - BEIJING, Aug. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading
SINOVAC REPORTS TOP-LINE PRELIMINARY RESULTS OF H1N1 VACCINE CLINICAL TRIALS - Results Show Good Safety Profile and Immunogenicity - BEIJING, Aug. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, announced today positive to
Read more →-SVA
May 6, 2009Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results Wednesday
to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial April 1, 2009, 8:00 am EDT April 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that it will host a conference call on Thurs
Read more →-SVA
May 6, 2009Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results - Conference call scheduled for Thursday
Reports Unaudited Full Year 2008 and Fourth Quarter Financial Conference call scheduled for Thursday, April 9, 2009 at 9:00 a.m. ET Provides full year 2009 sales guidance of $55 million to $60 million Thursday April 9, 2009, 8:57 am EDT April 9 /PRNewswire-Asia/ -- Sinovac Bi
Read more →-SVA
May 6, 2009C O R R E C T I O N -- Sinovac Biotech Ltd./ In the news release, "Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables," issued earlier today by Sinovac Biotech Ltd. over P
O R R E C T I O N -- Sinovac Biotech Ltd./ news release, "Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables," issued earlier today by Sinovac Biotech Ltd. over PR Newswire Asia, we are advised by the company that the last sent
Read more →-SVA
May 1, 2009Sinovac Biotech Ltd. Files Annual Report on Form 20-F On Friday
Biotech Ltd. Files Annual Report on Form 20-F May 1, 2009, 12:37 pm EDT May 1 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has filed its Annual Report on Form 20-F with the U.S.
Read more →-SVA
Apr 30, 2009Sinovac Initiates Preparatory Activities for Swine Flu Vaccine On Thursday
Initiates Preparatory Activities for Swine Flu Vaccine Thursday April 30, 2009, 11:58 am EDT April 30 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that the Company has initiated prepara
Read more →-SVA
Apr 28, 2009Sinovac Receives RMB 87 Million Purchase Order for Healive from China's Ministry of Public Health On Tuesday
Receives RMB 87 Million Purchase Order for Healive from China's Ministry of Tuesday April 28, 2009, 8:00 am EDT April 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that the Company has rec
Read more →-SVA
Mar 9, 2009Sinovac Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise Status Monday
Biotech Co. Ltd., Sinovac's Beijing Subsidiary, Obtains High-Tech Enterprise March 9, 2009, 8:00 am EDT March 9 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading developer and provider of vaccines in China, announced today that the Chinese governme
Read more →-SVA
Jan 8, 2009Sinovac Announces that Government Investigation Rules Out Healive's Role in Child's Death - Autopsy Results Show the Death was Caused by Myocarditis - BEIJING, Dec. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alte
Announces that Government Investigation Rules Out Healive's Role in Child's Autopsy Results Show the Death was Caused by Myocarditis - Dec. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading provider of vaccines in China, today provided an update
Read more →-SVA
Dec 30, 2008Sinovac Named to Zhongguancun's Top 20 Most Influential Brands Monday December 22, 8:00 am ET BEIJING, Dec. 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading provider of vaccines in China,
Named to Zhongguancun's Top 20 Most Influential Brands December 22, 8:00 am ET Dec. 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading provider of vaccines in China, today announced that it was recognized as one of Zhongguancun's Top 20 Most Infl
Read more →-SVA
Dec 4, 2008Sinovac Announces Share Repurchase Program Tuesday December 2, 8:00 am ET BEIJING, Dec. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading developer and provider of vaccines in China, announc
Announces Share Repurchase Program December 2, 8:00 am ET Dec. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading developer and provider of vaccines in China, announced today that its Board of Directors has authorized a program to repurchase Sinov
Read more →-SVA
Nov 27, 2008Sinovac Releases Statement on Healive Vaccine Suspension Tuesday December 2, 7:00 am ET BEIJING, Dec. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading provider of vaccines in China, announc
Releases Statement on Healive Vaccine Suspension December 2, 7:00 am ET Dec. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading provider of vaccines in China, announced today that, the Health Services Bureau of Fengtai District in the City of Beij
Read more →-SVA
Nov 18, 2008Sinovac Reports Third Quarter 2008 Unaudited Financial Results - Conference Call on Tuesday
Reports Third Quarter 2008 Unaudited Financial Results Conference Call on Tuesday, November 18, 2008 at 8:00 p.m. ET - November 18, 2008 - Sinovac Biotech Ltd. (Amex: SVA), a leading developer and provider of vaccines in China, today announced the Company's financial results
Read more →-SVA
Nov 12, 2008Sinovac to Host Conference Call to Report Third Quarter 2008 Financial Results Wednesday
to Host Conference Call to Report Third Quarter 2008 Financial November 12, 2008, 8:00 am EST Nov. 12 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that it will host a conference call on Tuesday, Novem
Read more →-SVA
Nov 4, 2008Sinovac to Participate in Two Upcoming Investor Conferences Wednesday October 29, 8:00 am ET BEIJING, Oct. 29 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a vaccine-focused biotech company in China, an
to Participate in Two Upcoming Investor Conferences October 29, 8:00 am ET Oct. 29 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a vaccine-focused biotech company in China, announced today that it is scheduled to present at two upcoming investor conferences,
Read more →-SVA
Oct 31, 2008Sinovac Named to Deloitte Technology Fast 50 China Monday November 3, 8:00 am ET BEIJING, Nov. 3 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a vaccine-focused biotech company in China, announced toda
Named to Deloitte Technology Fast 50 China November 3, 8:00 am ET Nov. 3 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a vaccine-focused biotech company in China, announced today its Beijing-based subsidiary and main operating entity, Sinovac Beijing, was na
Read more →-SVA
Oct 10, 2008Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season Wednesday September 10, 9:35 pm ET BEIJING, Sept. 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vac
Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu September 10, 9:35 pm ET Sept. 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced the market launch of Anflu , a seasonal influenza vaccine,
Read more →-SVA
Oct 9, 2008SINOVAC'S CREDIT RATING UPGRADED TO AAZ, SECOND HIGHEST RATING -OBTAINS 10 MILLION RMB COMMERCIAL BANK LOAN WITH INTEREST PAYMENT SUBSIDY- Beijing
CREDIT RATING UPGRADED TO AAZ, SECOND HIGHEST RATING 10 MILLION RMB COMMERCIAL BANK LOAN WITH INTEREST PAYMENT SUBSIDY- October 9, 2008 - Sinovac Biotech Ltd. (Amex: SVA - News), a vaccine-focused biotech company in China, announced today that the Beijing Zhongguancun Enterpr
Read more →-SVA
Oct 8, 2008Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine Monday September 15, 8:00 am ET BEIJING, Sept. 15 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a leading provider of va
Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in September 15, 8:00 am ET Sept. 15 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced the initiation of clinical trials in Ukraine for its ina
Read more →-SVA
Oct 8, 2008Sinovac Biotech Holds Annual General Meeting BEIJING, September 18 -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled
Biotech Holds Annual General Meeting September 18 -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled for September 4, 2008 was held two weeks later, on September 18, the Sep
Read more →-SVA
Oct 8, 2008Sinovac Initiates Development of Vaccine Against Hand, Foot, and Mouth Disease Tuesday September 23, 8:00 am ET BEIJING, Sept. 23 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a leading developer and p
Initiates Development of Vaccine Against Hand, Foot, and Mouth Tuesday September 23, 8:00 am Sept. 23 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading developer and provider of vaccines in China, today announced it has initiated development of a vacci
Read more →-SVA
Sep 23, 2008Sinovac to Present at the 2008 UBS Global Life Sciences Conference Wednesday September 17, 8:00 am ET BEIJING, Sept. 17 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a vaccine-focused biotech company i
to Present at the 2008 UBS Global Life Sciences Conference September 17, 8:00 am ET Sept. 17 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a vaccine-focused biotech company in China, announced today that Mr. Weidong Yin, Chairman, president & CEO, will prese
Read more →-SVA
Sep 22, 2008Sinovac Biotech Increases Ownership Position in its Operating Subsidiary Sinovac Beijing Beijing
Biotech Increases Ownership Position in its Operating Subsidiary Sinovac September 22, 2008 - Sinovac Biotech Ltd. (Amex: SVA), a leading developer and provider of vaccines in China, today announced the increase of its ownership position in Sinovac Biotech Co., Ltd. (or Sinova
Read more →-SVA
Sep 4, 2008Sinovac Adjourns Annual General Meeting Thursday September 4, 6:45 am ET BEIJING, Sept. 4 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a leading provider of vaccines in China, today announced that its
Adjourns Annual General Meeting September 4, 6:45 am ET Sept. 4 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled for September 4, 2008 has been adjourn
Read more →-SVA
Sep 1, 2008Sinovac to Present at the Susquehanna Financial Group's Second Annual Beijing Management Summit Conference BEIJING
to Present at the Susquehanna Financial Group's Second Annual Beijing Management September 1, 2008 --- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that Mr. Weidong Yin, Chairman, President and CEO, is scheduled to present at th
Read more →-SVA
Aug 14, 2008Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders Monday August 11, 8:00 am ET BEIJING, Aug. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a vaccine-focused biotech company in China
Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders August 11, 8:00 am ET Aug. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a vaccine-focused biotech company in China, announced today that it will hold its 2007 Annual Meeting of Shareholders on Th
Read more →-SVA
Aug 13, 2008Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results - Conference Call on Wednesday
Reports Record Second Quarter 2008 Unaudited Financial Results Conference Call on Wednesday, August 13, 2008 at 9:00 a.m. ET - August 13, 2008 - Sinovac Biotech Ltd. (Amex: SVA), a leading developer and provider of vaccines in China, today announced the Company's financial res
Read more →-SVA
Aug 7, 2008Sinovac to Host Conference Call to Report Second Quarter 2008 Financial Results Beijing
to Host Conference Call to Report Second Quarter 2008 Financial Beijing - August 7, 2008 - Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, today announced that it will host a conference call on Wednesday, August 13, 2008 at 9:00 a.m. ET to review
Read more →-SVA
Jul 2, 2008Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine BEIJING, June 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today a
Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine BEIJING, June 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the initiation of volunteer enrollment in its Pha
Read more →-SVA
Jun 16, 2008Sinovac Receives Healive and Bilive Purchase Orders from Provincial CDCs for Earthquake Disaster Areas BEIJING
Sinovac Receives Healive and Bilive Purchase Orders from Provincial CDCs for Earthquake Disaster Areas BEIJING, June 16, 2008-- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that the Shanxi Center for Disease Control and Prevention (C
Read more →-SVA
Jun 3, 2008Sinovac Delivers 80,000 Doses of Bilive to Gansu Earthquake Disaster Area Wednesday June 11, 8:00 am ET BEIJING, June 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a leading provider of vaccines in
Sinovac Delivers 80,000 Doses of Bilive to Gansu Earthquake Disaster Area Wednesday June 11, 8:00 am ET BEIJING, June 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that the Municipal Health Bureau and
Read more →-SVA
May 29, 2008Sinovac Receives RMB 20 Million Purchase Order for Healive from China's Ministry of Health to Vaccinate Earthquake Victims Tuesday May 27, 10:41 am ET BEIJING, May 27 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SV
Sinovac Receives RMB 20 Million Purchase Order for Healive from China's Ministry of Health to Vaccinate Earthquake Victims Tuesday May 27, 10:41 am ET BEIJING, May 27 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today
Read more →-SVA
May 23, 2008Sinovac Provides Support to China's Ministry of Health to Aid Earthquake Victims Wednesday May 21, 2:00 pm ET BEIJING, May 21 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines
Sinovac Provides Support to China's Ministry of Health to Aid Earthquake Victims Wednesday May 21, 2:00 pm ET BEIJING, May 21 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that it is providing immediate
Read more →-SVA
May 20, 2008Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results Tuesday March 25, 8:30 am ET BEIJING, March 25 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a leading prov
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results Tuesday March 25, 8:30 am ET BEIJING, March 25 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that it will hos
Read more →-SVA
May 16, 2008Sinovac Reports First Quarter 2008 Unaudited Financial Results Friday May 16, 8:00 am ET -- Conference Call on Friday
Sinovac Reports First Quarter 2008 Unaudited Financial Results Friday May 16, 8:00 am ET -- Conference Call on Friday, May 16, 2008 at 9:00 a.m. ET -- BEIJING, May 16 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading developer and provider of vaccines i
Read more →-SVA
May 16, 2008Sinovac to Host Conference Call to Report First Quarter 2008 Financial Results Thursday May 15, 8:00 am ET BEIJING, May 15 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in
Sinovac to Host Conference Call to Report First Quarter 2008 Financial Results Thursday May 15, 8:00 am ET BEIJING, May 15 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that it will host a conference cal
Read more →-SVA
May 9, 2008Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008 Wednesday May 7, 8:00 am ET BEIJING, May 7 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA -
Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008 Wednesday May 7, 8:00 am ET BEIJING, May 7 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today ann
Read more →-SVA
Apr 2, 2008Sinovac Receives China State Food and Drug Administration (SFDA) Approval for Pandemic Influenza H5N1 Vaccine Wednesday April 2, 8:00 am
Sinovac Receives China State Food and Drug Administration (SFDA) Approval for Pandemic Influenza H5N1 Vaccine Wednesday April 2, 8:00 am ET BEIJING, April 2, 2008 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading China-based biopharmaceutical company foc
Read more →-SVA
Mar 31, 2008Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results Monday March 31, 1:00 am ET -- Third Sequential Profitable Quarter -- -- Conference Call on Monday
Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results Monday March 31, 1:00 am ET -- Third Sequential Profitable Quarter -- -- Conference Call on Monday, March 31, 2008 at 9:00 a.m. ET -- BEIJING, March 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA -
Read more →-SVA
Mar 25, 2008Sinovac Announces Adjournment of Annual General Meeting Tuesday March 25, 3:00 am ET BEIJING, March 25 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announ
Sinovac Announces Adjournment of Annual General Meeting Tuesday March 25, 3:00 am ET BEIJING, March 25 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled f
Read more →-SVA
Mar 25, 2008Sinovac Biotech Holds Annual General Meeting Thursday April 10, 8:00 am ET BEIJING, April 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that i
Sinovac Biotech Holds Annual General Meeting Thursday April 10, 8:00 am ET BEIJING, April 10 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled for March 2
Read more →-SVA
Mar 24, 2008Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China Beijing
Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China Beijing March 24, 2008 Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that Mr. Weidong Yin, CEO, Ms. Nan Wang, Vice President, Ms. Helen Yang, Internati
Read more →-SVA
Jan 23, 2008Sinovac Announces $9.75 Million Private Placement Beijing
Sinovac Announces $9.75 Million Private Placement Beijing January 23, 2008 Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that it entered into a securities purchase agreement in connection with a private placement to an institutional a
Read more →-SVA
Dec 24, 2007Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine Beijing
Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine Beijing December 24, 2007 Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced positive top-line results of completed Phase II clinical tr
Read more →-SVA
Nov 1, 2007Sinovac Enters Purchase Agreement with Beijing Public Health Bureau for Anflu, Sinovac's Seasonal Influenza Vaccine Monday October 22, 8:00 am ET BEIJING, Oct. 22 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA -
Sinovac Enters Purchase Agreement with Beijing Public Health Bureau for Anflu, Sinovac's Seasonal Influenza Vaccine Monday October 22, 8:00 am ET BEIJING, Oct. 22 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in
Read more →-SVA
Nov 1, 2007Sinovac to Present at 2007 UBS Global Life Sciences Conference Monday September 17, 8:00 am ET BEIJING, Sept. 17 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading China-based biotech company focus
Sinovac to Present at 2007 UBS Global Life Sciences Conference Monday September 17, 8:00 am ET BEIJING, Sept. 17 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading China-based biotech company focusing on human vaccine development, today announced today it
Read more →-SVA
Nov 1, 2007Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine Tuesday September 11, 8:00 am ET BEIJING, Sept. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News)
Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine Tuesday September 11, 8:00 am ET BEIJING, Sept. 11 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading China-based biopharmaceutical company focusing
Read more →-SVA
Nov 1, 2007Sinovac Announces Postponement of Annual General Meeting Monday August 20, 8:49 pm ET BEIJING, Aug. 20 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in C
Sinovac Announces Postponement of Annual General Meeting Monday August 20, 8:49 pm ET BEIJING, Aug. 20 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, notified its shareholders today that the Annual Gene
Read more →-SVA
Nov 1, 2007Sinovac Reports First Half 2007 Financial Results Thursday August 16, 8:00 am ET First Half 2007 Highlights -- Sales increased 189% year-over-year to $13.5 million -- Gross profit grew 210% year-over-year to $11.6 millio
Sinovac Reports First Half 2007 Financial Results Thursday August 16, 8:00 am ET First Half 2007 Highlights -- Sales increased 189% year-over-year to $13.5 million -- Gross profit grew 210% year-over-year to $11.6 million -- Operating income rose to US$6.1 million, up from a
Read more →-SVA
Aug 17, 2007Sinovac Commences Vaccination of Volunteers for the Clinical Research of Pandemic Influenza Vaccine (H5N1) Tuesday August 14, 8:00 am ET BEIJING, Aug. 14 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a
Sinovac Commences Vaccination of Volunteers for the Clinical Research of Pandemic Influenza Vaccine (H5N1) Tuesday August 14, 8:00 am ET BEIJING, Aug. 14 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a China-based biopharmaceutical company focusing on vaccine
Read more →-SVA
Aug 16, 2007Semiannual Report For the Six Months Ended
For the Six Months Ended June 30, 2007 Unless otherwise indicated, references in this semi-annual report to: "$" and "U.S. dollars" are to the legal currency of the United States; "China" and the "PRC" are to the People's Republic of China, excluding, for the purposes of this
Read more →-SVA
Aug 15, 2007Sinovac Schedules First Half 2007 Financial Results Date Monday August 13, 8:00 am ET BEIJING, Aug. 13 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in C
Sinovac Schedules First Half 2007 Financial Results Date Monday August 13, 8:00 am ET BEIJING, Aug. 13 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today announced that it will release financial resul
Read more →-SVA
Aug 3, 2007Sinovac Enters Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd. Wednesday August 1, 8:00 am ET BEIJING, Aug. 1 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a lead
Sinovac Enters Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd. Wednesday August 1, 8:00 am ET BEIJING, Aug. 1 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today
Read more →-SVA
Aug 2, 2007Sinovac Schedules Annual General Meeting Tuesday July 31, 8:00 am ET BEIJING, July 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, announced t
Sinovac Schedules Annual General Meeting Tuesday July 31, 8:00 am ET BEIJING, July 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, announced today that it will hold its Annual General Meeting on Tuesd
Read more →-SVA
Aug 1, 2007Sinovac Receives Full Payment for Heping Wang's Obligations Friday July 27, 8:00 am ET BEIJING, July 27 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a China-based vaccine company, announced today that
Sinovac Receives Full Payment for Heping Wang's Obligations Friday July 27, 8:00 am ET BEIJING, July 27 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a China-based vaccine company, announced today that it has received full payment of Heping Wang's outstanding
Read more →-SVA
Aug 1, 2007Sinovac Issues Corporate Update Friday June 1, 4:30 pm ET BEIJING, June 1 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a vaccine-focused biotech company in China, today issued a corporate update. As pr
Sinovac Issues Corporate Update Friday June 1, 4:30 pm ET BEIJING, June 1 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a vaccine-focused biotech company in China, today issued a corporate update. As previously disclosed in Sinovac's annual report on Form 20-
Read more →-SVA
May 14, 2007Sinovac Schedules 2006 Financial Results Date Monday April 9, 8:00 am ET BEIJING, April 9 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today a
Sinovac Schedules 2006 Financial Results Date Monday April 9, 8:00 am ET BEIJING, April 9 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today announced that it will release financial results for the tw
Read more →-SVA
May 14, 2007Sinovac Reports First Quarter 2007 Unaudited Sales Thursday April 12, 8:00 am ET BEIJING, April 12 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China
Sinovac Reports First Quarter 2007 Unaudited Sales Thursday April 12, 8:00 am ET BEIJING, April 12 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today announced unaudited sales revenue for the first qu
Read more →-SVA
May 14, 2007Sinovac Reports 2006 Financial Results Thursday April 12, 8:00 am ET BEIJING, April 12 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today anno
Sinovac Reports 2006 Financial Results Thursday April 12, 8:00 am ET BEIJING, April 12 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today announced audited financial results for the year ended Decembe
Read more →-SVA
May 14, 2007Sinovac Commences Phase II Clinical Trials for Pandemic Influenza Vaccine (H5N1) Wednesday May 9, 8:20 am ET BEIJING, May 9 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmac
Sinovac Commences Phase II Clinical Trials for Pandemic Influenza Vaccine (H5N1) Wednesday May 9, 8:20 am ET BEIJING, May 9 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today announced that the China
Read more →-SVA
May 8, 2007Sinovac to Present at 2007 UBS Global Generic and Specialty Pharmaceuticals Conference Monday April 30, 8:00 am ET BEIJING, April 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of b
Sinovac to Present at 2007 UBS Global Generic and Specialty Pharmaceuticals Conference Monday April 30, 8:00 am ET BEIJING, April 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, announced today that i
Read more →-SVA
Mar 13, 2007Sinovac Provides Update on Study of Third Dose of Its Pandemic Influenza Vaccine Tuesday March 6, 8:00 am ET BEIJING, March 6 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharm
Sinovac Provides Update on Study of Third Dose of Its Pandemic Influenza Vaccine Tuesday March 6, 8:00 am ET BEIJING, March 6 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today announced an update for
Read more →-SVA
Feb 12, 2007Sinovac Files Registration Documents for Euvax-B(TM) with SFDA Loan Repayment Received from One Former Director Thursday February 8, 8:00 am ET BEIJING, Feb. 8 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - New
Sinovac Files Registration Documents for Euvax-B(TM) with SFDA Loan Repayment Received from One Former Director Thursday February 8, 8:00 am ET BEIJING, Feb. 8 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in Ch
Read more →-SVA
Feb 6, 2007Sinovac Schedules Investor Conference Call for
Sinovac Schedules Investor Conference Call for February 6, 2007 Friday February 2, 9:00 am ET BEIJING, Feb. 2 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, today announced that it has scheduled an i
Read more →-SVA
Feb 5, 2007Sinovac Clarifies Position on Restructuring Involving Its Chinese Subsidiary Wednesday January 31, 8:30 am ET BEIJING, Jan. 31 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex: SVA - News; the Company ) noted today t
Sinovac Clarifies Position on Restructuring Involving Its Chinese Subsidiary Wednesday January 31, 8:30 am ET BEIJING, Jan. 31 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex: SVA - News; the "Company") noted today that China Bioway Biotech Group Co., Ltd. ("China Bioway")
Read more →-SVA
Jan 22, 2007Sinovac Reports Fourth Quarter 2006 Unaudited Sales and Provides Corporate Update for 2007 Tuesday January 16, 8:30 am ET 4Q2006 Unaudited Sales Increases 56.75% to US$6.27 Million Compared to Audited Sales for the Same
Sinovac Reports Fourth Quarter 2006 Unaudited Sales and Provides Corporate Update for 2007 Tuesday January 16, 8:30 am ET 4Q2006 Unaudited Sales Increases 56.75% to US$6.27 Million Compared to Audited Sales for the Same Period of 2005 BEIJING, Jan. 16 /PRNewswire-FirstCall/ --
Read more →-SVA
Nov 30, 2006Sinovac Issues Corporate Update Tuesday November 28, 7:30 am ET BEIJING, Nov. 28 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a leading provider of biopharmaceutical products in China, issues a corpor
Sinovac Issues Corporate Update Tuesday November 28, 7:30 am ET BEIJING, Nov. 28 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, issues a corporate update today. The unaudited sales of third quarter 200
Read more →-SVA
Oct 18, 2006Sinovac Biotech Ltd. Engages The Ruth Group as Investor Relations And Public Relations Counsel Monday October 16, 7:30 am ET BEIJING, Oct. 16 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading prov
Sinovac Biotech Ltd. Engages The Ruth Group as Investor Relations And Public Relations Counsel Monday October 16, 7:30 am ET BEIJING, Oct. 16 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, announced tod
Read more →-SVA
Sep 29, 2006Sinovac Biotech Ltd. Announces First Sales of its Seasonal Influenza Vaccine, Anflu(TM) Wednesday September 27, 7:30 am ET BEIJING, Sept. 27 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ) announced today
Sinovac Biotech Ltd. Announces First Sales of its Seasonal Influenza Vaccine, Anflu(TM) Wednesday September 27, 7:30 am ET BEIJING, Sept. 27 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News) announced today that the third product of the Company, seasonal influenza
Read more →-SVA
Sep 12, 2006Sinovac Announces Its Clinical Trial Results of a Pandemic Influenza (H5N1) Vaccine Are Published by The Lancet BEIJING, Sept. 7 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Sinovac) (Amex: SVA - News) announced that its
Sinovac Announces Its Clinical Trial Results of a Pandemic Influenza (H5N1) Vaccine Are Published by The Lancet BEIJING, Sept. 7 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Sinovac) (Amex: SVA - News) announced that its paper of clinical trial results, named 'Safety and immuno
Read more →-SVA
Aug 31, 2006Preliminary Result of Phase I Clinical Trial Shows That Sinovac's Pandemic Influenza Vaccine (H5N1) has High Safety and Immunogenicity Profile Monday August 28, 8:30 am ET BEIJING, Aug. 28 /Xinhua-PRNewswire/ -- Sinovac
Preliminary Result of Phase I Clinical Trial Shows That Sinovac's Pandemic Influenza Vaccine (H5N1) has High Safety and Immunogenicity Profile Monday August 28, 8:30 am ET BEIJING, Aug. 28 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (AMEX: SVA - News), announced that the preli
Read more →-SVA
Jul 31, 2006Sinovac Biotech Ltd. Changes Its Contact for Investor Relations BEIJING, Aug. 1 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News ), a leading provider of biopharmaceutical products in China, announced today
Sinovac Biotech Ltd. Changes Its Contact for Investor Relations BEIJING, Aug. 1 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, announced today that it has changed its primary contact for investor relatio
Read more →-SVA
Jul 21, 2006Ludlow Capital Adds Sinovac to China Small Cap Index BEIJING, July 19 /Xinhua-PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, announced today t
Ludlow Capital Adds Sinovac to China Small Cap Index BEIJING, July 19 /Xinhua-PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of biopharmaceutical products in China, announced today that it has been added as a component of the Ludlow China Sm
Read more →-SVA
Jul 17, 2006Sinovac Reports Fiscal 2005 Results BEIJING, July 14 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. ( AMEX : SVA ), a leading provider of biopharmaceutical products in China, announced financial results for its fiscal year
Sinovac Reports Fiscal 2005 Results BEIJING, July 14 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (AMEX: SVA), a leading provider of biopharmaceutical products in China, announced financial results for its fiscal year ended December 31, 2005. Sales increased 33.4% to $8,608,000 i
Read more →-SVA
Jun 30, 2006Sinovac Biotech Files Form 12b-25 with the U.S. Securities and Exchange Commission Beijing
Sinovac Biotech Files Form 12b-25 with the U.S. Securities and Exchange Commission Beijing, June 30, 2006 (Xinhua PR Newswire)---Sinovac Biotech Ltd. (AMEX: SVA) announced today that it has filed a Form 12b-25 (Notification of Late Filing) with the Securities and Exchange Commi
Read more →-SVA
Jun 16, 2006Sinovac Biotech Provides Administrative Updates Beijing
Sinovac Biotech Provides Administrative Updates Beijing, June 16, 2006 (Xinhua PR Newswire)---Sinovac Biotech Ltd. (AMEX: SVA) confirmed today, as previously announced in a United States Securities and Exchange Commission Form 6-K submission dated May 26, 2006, the resignation o
Read more →-SVA
May 30, 2006SINOVAC COMPLETES IMMUNIZATION SCHEDULE IN THE PHASE I CLINICAL TRIAL OF ITS PROPRIETARY AVIAN INFLUENZA VACCINE (H5N1) Beijing
SINOVAC COMPLETES IMMUNIZATION SCHEDULE IN THE PHASE I CLINICAL TRIAL OF ITS PROPRIETARY AVIAN INFLUENZA VACCINE (H5N1) Beijing, April 10, 2006 (Xinhua PR Newswire) -- Sinovac Biotech Ltd. (AMEX: SVA) announced today that all 120 volunteers in the Phase I clinical trial of its
Read more →-SVA
Apr 12, 2006Sinovac Biotech Ltd., and LG Life Sciences, Ltd. Announce Distribution Agreement to Market Vaccines in the Peoples Republic of China BEIJING, CHINA and SEOUL, REPUBLIC OF KOREA -- (Xinhua PR Newswire) Sinovac Biotech Ltd
Sinovac Biotech Ltd., and LG Life Sciences, Ltd. Announce Distribution Agreement to Market Vaccines in the Peoples Republic of China BEIJING, CHINA and SEOUL, REPUBLIC OF KOREA -- (Xinhua PR Newswire) Sinovac Biotech Ltd. ("Sinovac") (AMEX: SVA - News) and LG Life Sciences, Ltd
Read more →-SVA
Mar 2, 2006to the Form S-8, which was filed with the Securities and Exchange Commission on
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MARCH 22, 2006 Notice is hereby given that the Annual Meeting of Stockholders of Sinovac Biotech Ltd. (the "Corporation") will be held concurrently in Beijing, People's Republic of China ("PRC") and St. John's, Antigua, at
Read more →-SVA
Nov 9, 2005SINOVAC BIOTECH LTD. ANNOUNCES FIRST SALES OF ITS PROPRIETARY COMBINED HEPATITIS A&B VACCINE, BILIVE(TM) BEIJING-- (CCNMatthews)
SINOVAC BIOTECH LTD. ANNOUNCES FIRST SALES OF ITS PROPRIETARY COMBINED HEPATITIS A&B VACCINE, BILIVE(TM) BEIJING-- (CCNMatthews)--June 20, 2005--Sinovac Biotech Ltd. ("Sinovac") ("the Company") (AMEX:SVA - News) announced today that the first purchase order of Bilive(TM), Sinov
Read more →-SVA
Jun 16, 2005SINOVAC BIOTECH LTD., AND LG LIFE SCIENCES, LTD. ANNOUNCE THEIR LETTER OF INTENT FOR COLLABORATION IN GLOBAL MARKETING AND VACCINE SUPPLY BEIJING, CHINA and SEOUL, REPUBLIC OF KOREA --(BUSINESS WIRE) May18, 2005--Sinovac
SINOVAC BIOTECH LTD., AND LG LIFE SCIENCES, LTD. ANNOUNCE THEIR LETTER OF INTENT FOR COLLABORATION IN GLOBAL MARKETING AND VACCINE SUPPLY BEIJING, CHINA and SEOUL, REPUBLIC OF KOREA --(BUSINESS WIRE) May18, 2005--Sinovac Biotech Ltd. ("Sinovac") (AMEX:SVA - News), and LG Life
Read more →-SVA
Apr 21, 2005SINOVAC BIOTECH LTD. -------------------- UPDATES ON ITS AVIAN INFLUENZA VACCINE DEVELOPMENT -------------------------------------------------- BEIJING
SINOVAC BIOTECH 6K, PRESS RELEASE 3.2.05 SINOVAC BIOTECH LTD. -------------------- UPDATES ON ITS AVIAN INFLUENZA VACCINE DEVELOPMENT -------------------------------------------------- BEIJING, March 2, 2005 - Sinovac Biotech Ltd. ("Sinovac") ("the Company") (AMEX: SVA) upd
Read more →-SVA
Apr 18, 2005SINOVAC BIOTECH LTD. ISSUES CORPORATE UPDATE -------------------------------------------- BEIJING
SINOVAC 6K, PRESS RELEASE, 04.18.05 SINOVAC BIOTECH LTD. ISSUES CORPORATE UPDATE -------------------------------------------- BEIJING, April 18, 2005 - Sinovac Biotech Ltd. ("Sinovac") ("the Company") (AMEX: SVA) today updates on the status of the vaccines comprising its prod
Read more →-SVA
Feb 17, 2005SINOVAC BIOTECH LTD. -------------------- RELEASES FINANCIAL STATEMENTS FOR THE THIRD QUARTER AND NINE MONTHS ------------------------------------------------------------------- ENDING 30TH SEPTEMBER 2004 ---------------
SINOVAC BIOTECH 6K, PRESS RELEASE, 02.17.05 SINOVAC BIOTECH LTD. -------------------- RELEASES FINANCIAL STATEMENTS FOR THE THIRD QUARTER AND NINE MONTHS ------------------------------------------------------------------- ENDING 30TH SEPTEMBER 2004 -------------------------
Read more →-SVA
Feb 11, 2005SINOVAC BIOTECH LTD. COMPLETES THE ACQUISITION OF AN ADDITIONAL 20.56% OF ------------------------------------------------------------------------- SINOVAC (BEIJING) OPERATING SUBSIDIARY ---------------------------------
SINOVAC BIOTECH 6K, PRESS RELEASE, 02.09.05 SINOVAC BIOTECH LTD. COMPLETES THE ACQUISITION OF AN ADDITIONAL 20.56% OF ------------------------------------------------------------------------- SINOVAC (BEIJING) OPERATING SUBSIDIARY -------------------------------------- BEIJI
Read more →-SVA
Jan 10, 2005SINOVAC BIOTECH LTD. -------------------- REPORTS 2004 SALES GROWTH OF OVER 230% -------------------------------------- AND ANNOUNCES $1.475 MILLION PRIVATE FINANCING ---------------------------------------------- BEIJIN
SINOVAC BIOTECH 6K, PRESS RELEASE, 01.03.05 SINOVAC BIOTECH LTD. -------------------- REPORTS 2004 SALES GROWTH OF OVER 230% -------------------------------------- AND ANNOUNCES $1.475 MILLION PRIVATE FINANCING ---------------------------------------------- BEIJING, Januar
Read more →-SVA
Dec 21, 2004SINOVAC BIOTECH LTD. -------------------- ENTERS INTO FINANCIAL ADVISORY AGREEMENT ---------------------------------------- WITH CREDIT SUISSE ADVISORY PARTNERS A.G. ----------------------------------------- BEIJING
SINOVAC BIOTECH LTD. 6K, PRESS RELEASE, 12.21.04 SINOVAC BIOTECH LTD. -------------------- ENTERS INTO FINANCIAL ADVISORY AGREEMENT ---------------------------------------- WITH CREDIT SUISSE ADVISORY PARTNERS A.G. ----------------------------------------- BEIJING, Decembe
Read more →-SVA
Dec 16, 2004SINOVAC BIOTECH LTD. SIGNS AVIAN FLU VACCINE CO-DEVELOPMENT AGREEMENT --------------------------------------------------------------------- WITH CHINA CENTRE OF DISEASE CONTROL AND PREVENTION (CHINA CDC) ----------------
SINOVAC BIOTECH 6K, PRESS RELEASE, 12.16.04 SINOVAC BIOTECH LTD. SIGNS AVIAN FLU VACCINE CO-DEVELOPMENT AGREEMENT --------------------------------------------------------------------- WITH CHINA CENTRE OF DISEASE CONTROL AND PREVENTION (CHINA CDC) ----------------------------
Read more →-SVA
Dec 6, 2004SINOVAC BIOTECH LTD. -------------------- PHASE I HUMAN CLINICAL TRIAL SHOWS ITS SARS VACCINE TO ------------------------------------------------------ BE SAFE AND TO INDUCE SARS-NEUTRALIZING ANTIBODIES -----------------
SINOVAC BIOTECH 6K, PRESS RELEASE 12.06.04 SINOVAC BIOTECH LTD. -------------------- PHASE I HUMAN CLINICAL TRIAL SHOWS ITS SARS VACCINE TO ------------------------------------------------------ BE SAFE AND TO INDUCE SARS-NEUTRALIZING ANTIBODIES ----------------------------
Read more →-SVA
Nov 22, 2004SINOVAC BIOTECH LTD. -------------------- RELEASES FINANCIAL STATEMENTS FOR FIRST SIX MONTHS OF 2004 ---------------------------------------------------------- - SHOWING SALES INCREASE OF 110% ---------------------------
SINOVAC BIOTECH 6K, PRESS RELEASE, 11.22.04 SINOVAC BIOTECH LTD. -------------------- RELEASES FINANCIAL STATEMENTS FOR FIRST SIX MONTHS OF 2004 ---------------------------------------------------------- - SHOWING SALES INCREASE OF 110% -------------------------------- BEI
Read more →-SVA
Nov 18, 2004SINOVAC BIOTECH LTD. ISSUES CORPORATE UPDATE ON ----------------------------------------------- APPROVAL OF ITS HEPATITIS A & B VACCINE (BILIVETM) AND ITS APPLICATION TO THE ----------------------------------------------
SINOVAC BIOTECH 6K, PRESS RELEASE, 10.13.04 SINOVAC BIOTECH LTD. ISSUES CORPORATE UPDATE ON ----------------------------------------------- APPROVAL OF ITS HEPATITIS A & B VACCINE (BILIVETM) AND ITS APPLICATION TO THE ----------------------------------------------------------
Read more →-SVA
Oct 6, 2004SINOVAC BIOTECH LTD. -------------------- UPDATES ON PHASE I HUMAN CLINICAL TESTING OF SARS VACCINE --------------------------------------------------------- - ALL 36 SUBJECTS HAVE NOW RECEIVED TWO INOCULATIONS AND THE -
SINOVAC BIOTECH LTD. 6K, PRESS RELEASE, 09.07.04 SINOVAC BIOTECH LTD. -------------------- UPDATES ON PHASE I HUMAN CLINICAL TESTING OF SARS VACCINE --------------------------------------------------------- - ALL 36 SUBJECTS HAVE NOW RECEIVED TWO INOCULATIONS AND THE ------
Read more →-SVA
Sep 16, 2004SINOVAC BIOTECH LTD. -------------------- UPDATES ON PHASE I HUMAN CLINICAL TESTING OF SARS VACCINE --------------------------------------------------------- ALL 36 SUBJECTS HAVE NOW BEEN INOCULATED WITH EITHER SARS VACC
SINOVAC BIOTECH 6K, PRESS RELEASE 8.9.04 SINOVAC BIOTECH LTD. -------------------- UPDATES ON PHASE I HUMAN CLINICAL TESTING OF SARS VACCINE --------------------------------------------------------- ALL 36 SUBJECTS HAVE NOW BEEN INOCULATED WITH EITHER SARS VACCINE OR PLACEBO
Read more →-SVA
Aug 18, 2004SINOVAC BIOTECH LTD. -------------------- HAS RECEIVED OVER US $1 MILLION IN GOVERNMENT RESEARCH FUNDING FOR SARS ----------------------------------------------------------------------- VACCINE ------- BEIJING, 1 June, 2
SINOVAC BIOTECH 6K, PRESS RELEASE 06.01.04 SINOVAC BIOTECH LTD. -------------------- HAS RECEIVED OVER US $1 MILLION IN GOVERNMENT RESEARCH FUNDING FOR SARS ----------------------------------------------------------------------- BEIJING, 1 June, 2004 - Sinovac Biotech Ltd. (
Read more →-SVA
Mar 23, 2004SINOVAC BIOTECH LTD. -------------------- HAS INITIATED NEW HUMAN INFLUENZA VACCINE R&D PROJECT AND IS EXPECTED TO ------------------------------------------------------------------------ COMPLETE PRE-CLINICAL RESEARCH B
SINOVAC BIOTECH LTD. 6K, PRESS RELEASE SINOVAC BIOTECH LTD. -------------------- HAS INITIATED NEW HUMAN INFLUENZA VACCINE R&D PROJECT AND IS EXPECTED TO ------------------------------------------------------------------------ COMPLETE PRE-CLINICAL RESEARCH BY THE END OF THI
Read more →-SVA
Jan 29, 2004SINOVAC BIOTECH LTD. -------------------- (formerly Net-Force Systems Inc.) Pro-forma Consolidated Financial Statements (Expressed in U.S. Dollars)
SINOVAC BIOTECH LTD. 6K/A #2, PRO FORMA FINANCIAL SINOVAC BIOTECH LTD. -------------------- (formerly Net-Force Systems Inc.) Pro-forma Consolidated Financial Statements (Expressed in U.S. Dollars) --------------------------- Accountant's Compilation Report Pro-forma Cons
Read more →-SVA
Oct 31, 2003NET FORCE SYSTEMS INC.SIGNS LETTER OF INTENT TO ACQUIRE TANGSHAN YIAN BIOLOGICAL ENGINEERING CO., LTD. ---------------------------------------------- BEIJING
NET FORCE SYSTEMS 6K, PRESS RELEASE 10.31.03 NET FORCE SYSTEMS INC.SIGNS LETTER OF INTENT TO ACQUIRE TANGSHAN YIAN BIOLOGICAL ENGINEERING CO., LTD. ---------------------------------------------- BEIJING, October 31, 2003 (BUSINESS WIRE) -- Net Force Systems Inc. ("Net Force"
Read more →-SVA
Oct 29, 2003NET-FORCE
NET FORCE SYSTEMS 6K, FINANCIALS, NET FORCE NET-FORCE SYSTEMS INC. AND SUBSIDARY CONSOLIDATED FINANCIAL STATEMENTS April 30, 2003 and 2002 Independent Auditors' Report............................................... F-3 Consolidated Balance Sheets.............................
Read more →Competitive Position
How SVA ranks across every disease it competes inCompetitive Position is a premium feature
See how SVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial